Oxazinone compound
A novel oxazinone compound activates aryl hydrocarbon receptors to enhance skin barrier function and reduce inflammation, addressing the safety concerns of existing treatments by degrading in the blood, thus preventing accumulation and side effects.
Patent Information
- Application Number
- PCT/KR2026/005942
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for inflammatory skin diseases and autoimmune diseases, such as atopic dermatitis, using topical corticosteroids and calcineurin inhibitors, pose risks of side effects like skin atrophy, vasodilation, adrenal suppression, and systemic immunosuppression due to accumulation in the body, necessitating the development of safer therapeutic agents that activate aryl hydrocarbon receptors for anti-inflammatory and antioxidant effects.
A novel oxazinone compound that binds to and activates aryl hydrocarbon receptors, enhancing skin barrier function and antioxidant responses, while degrading upon exposure to blood to minimize accumulation and side effects.
The compound effectively strengthens the skin barrier, reduces inflammation, and suppresses hyperimmunity without causing systemic side effects by degrading in the blood, offering a safer treatment for inflammatory and autoimmune diseases.
Smart Images

Figure KR2026005942_12112026_PF_FP_ABST
Abstract
Description
oxazinone compounds
[0001] The present invention relates to a novel oxazinone compound useful for the prevention, improvement, or treatment of inflammatory diseases by binding to and activating an aryl hydrocarbon receptor (AhR) to regulate inflammation-related factors, pharmaceutical compositions, cosmetic and food compositions containing the same, methods for preparing the same, and uses of said compound. This application claims the benefit of priority based on Korean Patent Application No. 10-2025-0060016 filed on May 8, 2025, and all contents disclosed in the document of said Korean Patent Application are incorporated herein as part of this specification.
[0002] Aryl hydrocarbon receptors (AhRs) are present on the surface of cells, particularly immune cells and epithelial cells, and are involved in cell development, growth, and reproduction. They are activated by various external environmental pollutants, dietary components, microbial metabolites, and endogenous metabolites. Activated aryl hydrocarbon receptors perform major physiological functions in vivo, such as maintaining cellular homeostasis, detoxification, regulating immune responses, maintaining skin barrier function, inducing anti-inflammatory responses, and antioxidant responses. They play a key role in defense mechanisms against external stimuli and pathogens, as well as in regulating inflammation. In particular, activated aryl hydrocarbon receptors play an important role in maintaining skin homeostasis because they promote the expression of genes related to the maintenance and restoration of skin barrier function.
[0003] Reduced activity or dysfunction of aryl hydrocarbon receptors can lead to pathological conditions, such as the disruption of immune homeostasis and the over-induction of inflammatory responses, and may be involved in the development and exacerbation of various skin diseases, inflammatory diseases, and autoimmune diseases. Therefore, regulating AhR activity can be an effective means for the prevention or treatment of the aforementioned diseases.
[0004] Meanwhile, topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) are used to treat atopic dermatitis, a representative inflammatory skin disease. Although TCS rapidly alleviate inflammatory responses through potent anti-inflammatory effects and the suppression of inflammatory cytokine expression, long-term or repeated use can lead to local side effects such as skin atrophy and vasodilation, as well as serious side effects like adrenal suppression and growth retardation due to accumulation in the body. TCIs can relieve skin inflammation by inhibiting calcineurin, thereby suppressing T-cell activation and the production of inflammatory cytokines. However, TCIs can also accumulate in the body and be absorbed systemically with long-term, repeated use, raising concerns about the potential development of lymphoma and skin cancer due to systemic immunosuppression.
[0005] Therefore, there is a need for the development of new therapeutic agents that demonstrate therapeutic efficacy against various skin diseases, inflammatory diseases, and autoimmune diseases through powerful antioxidant and anti-inflammatory activities, while also being safely degradable within the body to reduce the potential for accumulation and exposure and prevent side effects.
[0006] [Prior Art Literature]
[0007] [Patent Literature]
[0008] (Patent Document 1) Republic of Korea Published Patent Application No. 10-2013-0059400
[0009] The present invention aims to provide a novel compound that exhibits efficacy in improving, preventing, and / or treating skin diseases, inflammatory diseases, or autoimmune diseases through the activation of aryl hydrocarbon receptors, while degrading upon exposure to blood, thereby having a low potential for accumulation and exposure in the body.
[0010] Accordingly, the present invention provides a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, hydrate, solvate, polymorph, or isotopic variant thereof (hereinafter also simply referred to as "compound, etc."):
[0011] [Chemical Formula 1]
[0012]
[0013] (In the above formula, the definitions of each term are explained in detail below)
[0014]
[0015] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of skin diseases, inflammatory diseases, or autoimmune diseases, comprising the above-mentioned compound, etc., as an active ingredient.
[0016] In addition, the present invention provides a food composition for the prevention or improvement of skin diseases, inflammatory diseases, or autoimmune diseases, comprising the above-mentioned compound, etc., as an active ingredient.
[0017] In addition, the present invention provides a cosmetic composition for the prevention or improvement of skin diseases, comprising the above-mentioned compound, etc., as an active ingredient.
[0018] In addition, the present invention provides a composition for enhancing the activity of an aryl hydrocarbon receptor, comprising the above-mentioned compound, etc., as an active ingredient.
[0019] However, the technical problems that the present invention aims to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by those skilled in the art to which the present invention belongs from the description below.
[0020] The compound of Formula 1 according to the present invention can induce the enhancement of activity of aryl hydrocarbon receptors to exhibit skin barrier strengthening, antioxidant, and anti-inflammatory effects, and since it decomposes upon exposure to blood, the possibility of accumulation in the body and side effects is low, so it can be usefully used for the improvement, prevention, and / or treatment of atopic dermatitis.
[0021] FIG. 1 shows the increase in expression of skin barrier-related genes (FLGN) and Nqo1 (antioxidant-related genes) by a compound according to one embodiment of the present invention (Example 30 (Ex30), Example 45 (Ex45), or Example 65 (Ex65)) (ref. 1 refers to Comparative Example 1, Co refers to a control group not treated with the compounds of the present invention, the same applies hereinafter).
[0022] FIG. 2 shows the results of administering a compound according to one embodiment of the present invention (Example 30 (Ex30) or Example 45 (Ex45)) to an atopic mouse model, showing reduced ear thickness, ear weight (ref. 1), which reflect the degree of inflammatory response and edema, and reduced IgE (ref. 1), which indicates the degree of hyperimmune and allergic inflammatory response, compared to mice administered the comparative example. Meanwhile, the Sham group refers to a control group in which atopy is not induced, and the vehicle group refers to a solvent-treated control group in which atopy is induced.
[0023] The present invention aims to provide a novel compound that induces the activation of aryl hydrocarbon receptors to exhibit efficacy in improving, preventing, and / or treating skin diseases, inflammatory diseases, or autoimmune diseases, while degrading upon exposure to blood, thereby having a low potential for accumulation and exposure in the body.
[0024] The present invention will be described in detail below.
[0025] Unless otherwise stated below, the "compound represented by Chemical Formula 1" of the present invention includes all pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, hydrates, solvates, polymorphs, and / or isotopic variants thereof, all of which should be interpreted as being included within the scope of the present invention. For convenience of explanation, the term may be simply abbreviated in this specification as "compound of Chemical Formula 1," etc.
[0026]
[0027] Definition of Terms
[0028] The definitions of residues used in this specification are described below. In addition, where no separate definition is provided, residues are used in the sense generally understood by those skilled in the art.
[0029] The term "independently" as used in this specification means that when more than one substituent is selected from a plurality of possible substituents, these substituents may be identical or different from each other.
[0030] As used herein, the terms “arbitrarily substituted” or “substituted” indicate the replacement of one or more hydrogen atoms with monovalent or divalent radicals. If the substituted substituent comprises a straight-chain group, the substitution may occur within the chain (e.g., 2-hydroxypropyl, 2-aminobutyl, etc.) or at the chain ends (e.g., 2-hydroxyethyl, 3-cyanopropyl, etc.). The substituted substituent may be a straight-chain, branched-chain, or cyclic arrangement of covalently bonded carbons or heteroatoms. It is understood that the above definition is not intended to include unacceptable substitution patterns (e.g., methyl substituted with five fluorogroups, or halogen atoms substituted with other halogen atoms). Such unacceptable substitution patterns are known to those skilled in the art.
[0031] As used in this specification, the terms “halo,” “halogen,” or “halide(s)” represent F, Cl, Br, or I.
[0032] As used herein, "alkyl" refers to an aliphatic hydrocarbon radical and may include both linear and branched hydrocarbon radicals, and includes structural isomers. For example, C 1-6 The alkyl group is an aliphatic hydrocarbon having 1 to 6 carbon atoms and may be methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, and 2-ethylbutyl. In the present invention, the alkyl group is C 1-20 , C 1-15 , C 1-12 , C 1-10 , C 1-8 , C 1-6 , C 1-5 , C 1-4 , C 1-3 , or C 1-2 It may be an alkyl, but is not limited thereto.
[0033] As used herein, the term "haloalkyl" means an alkyl group substituted with one or more, for example, 1 to 3, or 1 to 4, halogen atoms, and said alkyl is defined as above. "Halo" indicates F, Cl, Br, or I, and the term is used interchangeably with the term "halogen." For example, haloalkyl means fluoromethyl, difluoromethyl, chloromethyl, trifluoromethyl, or 2,2,2-trifluoroethyl.
[0034] The term "alkoxy" as used in this specification refers to an -O-alkyl or alkyl-O-group, and the alkyl is defined as above. For example, it may be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, and t-butoxy.
[0035] As used in this specification, the term "amino" refers to -NH2; and "nitro" refers to -NO2. "Aminoalkyl" means an alkyl group substituted with one or more amino groups, wherein the alkyl is defined as above.
[0036] As used herein, "cycloalkyl" refers to a cyclic alkyl that may be substituted or unsubstituted, for example, C3- 20 Cycloalkyl represents a monovalent saturated hydrocarbon ring system having 3 to 20 carbon atoms. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc.
[0037] As used herein, the terms “ring,” “cycle,” and “cyclic” refer to cyclic hydrocarbon groups and encompass concepts including monocyclic, bicyclic, tricyclic, or polycyclic structures. Additionally, as used herein, the term “ring” encompasses both fully saturated and partially unsaturated rings, and includes both aromatic and non-aromatic rings. “Heteroring” or “heterocycle” refers to a ring containing one or more heteroatoms. The term “membered,” used in conjunction with “ring,” refers to the number of skeletal atoms constituting the ring.
[0038] As used herein, the term "aryl" refers to an aromatic hydrocarbon group having a shared pi electron system and at least one ring. In the present invention, aryl is C 5-12 , C 5-11 , C 5-10 , C 5-9 , C 5-8 , C 5-7 , C 5-6 , C 6-12 , C 6-11 , C 6-10 , C 6-9 , C 6-8 , or C 6-7It may be an aryl, but is not limited thereto. The aryl includes monocyclic, bicyclic, tricyclic, or more polycyclic aryls. That is, the aryl may include a bicyclic radical comprising an aromatic ring fused to a saturated or partially unsaturated ring. Exemplary aryl groups include benzene (phenyl), substituted phenyl, biphenyl, naphthyl, toluyl, naphthalenyl, anthracenyl, indenyl, indanyl, etc., but are not limited thereto.
[0039] As used herein, “heterocycle” refers to an aromatic, saturated or partially unsaturated mono-, bi-, or poly-cyclic system containing a specified number of ring atoms, comprising one or more heteroatoms selected from N, O, and S ring members, wherein the heterocyclic ring may be connected to the base molecule through ring atoms. The bicyclic system may be connected via 1,1-fusion (spiro), 1,2-fusion (fused), or 1,2-fusion (bridgehead).
[0040] As used herein, the term "heteroaryl" refers to a monovalent or divalent substituent derived from a monoheterocyclic or polyheterocyclic aromatic hydrocarbon containing one or more heteroatoms selected from N, O, and S, preferably 1 to 3 or 1 to 2 heteroatoms. Examples of heteroaryls include, but are not limited to, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,2,4-oxazolyl, 3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, triazolyl, tetrazolyl, triazinyl, indolyl, etc. Examples of bicyclic heteroaryls include, but are not limited to, indolyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzthiadiazolyl, quinolinyl, isoquinolinyl, propyridinyl, and similar groups thereof.
[0041] As used herein, the term "heterocycloalkyl" refers to a monocyclic, bicyclic, tricyclic, or higher cyclic ring having 3 to 10 ring members containing one or more heteroatoms selected from N, O, and S, for example, 1 to 4, 1 to 3, or 1 to 2 heteroatoms. Additionally, the heterocycle according to the present invention may also be a fused or cross-linked heterocycloalkyl. Examples of heterocycloalkyls may include azetidineyl, oxetanyl, tetrahydrofuran, pyrrolidineyl, imidazolineyl, oxazolinyl, oxazolidineyl, piperidineyl, piperazineyl, tetrahydropyranyl, dihydropyranyl, tetrahydropyridineyl, dihydropyridineyl, dihydrothiopyranyl, tetrahydropyrimidineyl, tetrahydropyridazineyl, dihydropyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydropyrazolopyridineyl, morpholineyl, indolineyl, azethiomorpholineyl, etc.
[0042] The attachment of heterocycloalkyl substituents may occur through carbon atoms or heteroatoms. The heterocycloalkyl group may optionally be substituted with one or more suitable groups through one or more of the aforementioned groups.
[0043] The term "stereoisomer" refers to a set of compounds that have the same molecular formula and identical interatomic bonding connectivity, but differ in the three-dimensional arrangement of atoms. The term "stereoisomer" refers to any member of this set of compounds. For example, stereoisomers may be enantiomers or diastereomers.
[0044] The term "enantiomer" refers to a pair of stereoisomers that are mirror images of each other and cannot be superimposed. The term "enantiomer" refers to a single member of such a pair of stereoisomers. The term "racemic" refers to a 1:1 mixture of a pair of enantiomers.
[0045] The term "diastereoisomer" refers to a set of stereoisomers that cannot be superimposed by rotation around a single bond. For example, compounds containing cis- and trans- double bonds, endo- and exo- substitutions, and multiple stereochemical centers with different relative stereoconfigurations on a cyclic ring system are considered to be diastereoisomers. The term "diastereoisomer" refers to any member of this set of compounds. In some of the examples presented, the synthetic route may produce a single diastereoisomer or a mixture of diastereoisomers.
[0046] As used herein, the term "tautomer" refers to a type of structural isomer having the same chemical or molecular formula but different arrangements of constituent atoms, meaning that the structure changes by continuously switching back and forth between the two isomers, such as in a keto-enol structure.
[0047] The term "solvent" refers to a complex of variable stoichiometry formed by a solute and a solvent. For the purposes of this disclosure, such a solvent may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, MeOH, EtOH, and AcOH. A solvent in which water is the solvent molecule is referred to as a "hydrate." Hydrates include compositions containing stoichiometric amounts of water as well as compositions containing variable amounts of water.
[0048] As used herein, the term "polymorph" refers to a solid form having the same chemical formula but different molecular arrangements and crystal structures. The polymorph has a specific crystal structure and can be characterized by methods such as X-ray diffraction (XRD), infrared spectroscopy (IR), and dissimilar scintigraphy (DSC).
[0049] As used herein, the term “isotope variant” refers to a compound containing isotopes in a non-natural proportion in one or more atoms constituting the compound. Examples of isotopes that may be incorporated into the compound of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, iodine, and chlorine, such as 2H (deuterium), 3H, 11C, 13C, 14C, 18F, 123I, or 125I, etc., which may be naturally occurring or non-naturally occurring isotopes.
[0050]
[0051] Compound of Chemical Formula 1
[0052] To solve the above-mentioned problem, the present invention provides a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, hydrate, solvate, polymorph, or isotope variant thereof:
[0053] [Chemical Formula 1]
[0054]
[0055]
[0056] In the above chemical formula 1,
[0057] A is C 6-10 It is a 5- to 12-membered heteroaryl comprising 1 to 3 heteroatoms selected from the group consisting of aryl, N, O, and S, or a 7- to 12-membered bicyclic heterocycle comprising 1 to 3 heteroatoms selected from the group consisting of N, O, and S, and
[0058] R is H, C 1-10 Alkyl, OH, halo, C 1-10 Alkoxy, halo C 1-10 Alkyl, Hydroxy C 1-10 Alkyl, Halo C 1-6 Alkoxy, -C(=O)OR', C 3-8 Cycloalkyl or C 6-10 Arilgo,
[0059] X is H, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkinil, Halo, CN, C 1-10 Alkoxy, halo C 1-10 Alkyl, Halo C 1-10 Alkoxy, Hydroxy C 1-10 Alkyl, OH, C 3-8 Cycloalkyl, C 6-10 Aryl, 5- to 12-membered heterocycloalkyl or mono- or di-C 1-10 It is an alkylamino, and
[0060] R' is C 1-10 It is alkyl, and
[0061] n is an integer from 0 to 3.
[0062]
[0063] In one embodiment of the present invention, the heterocycloalkyl, heteroaryl, or bicyclic heteroring may include one to three heteroatoms selected from the group consisting of N, O, and S, and when including two or more heteroatoms, each heteroatom may be the same or different from each other.
[0064]
[0065] In one embodiment of the present invention, the A is C 6-10 It may be a 5- to 7-membered heteroaryl containing 1 to 3 heteroatoms selected from the group consisting of aryl, N, O, and S, or a 7- to 10-membered bicyclic heterocycle containing 1 to 3 heteroatoms selected from the group consisting of N, O, and S, but is not limited thereto.
[0066]
[0067] More specifically, the above A may be any one selected from the group consisting of the following, but is not limited thereto:
[0068]
[0069]
[0070] In one embodiment of the present invention, R is H, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, Halo C 1-6 Alkyl, Hydroxy C 1-6 Alkyl, Halo C 1-6 Alkoxy, -C(=O)OR', OH, F, Cl, Br, or phenyl, and R' is C 1-6 It may be an alkyl but is not limited thereto.
[0071]
[0072] More specifically, the above R may be H, methyl, ethyl, methoxy, ethoxy, isopropoxy, t-butoxycarbonyl, cyclopropyl, OH, CF3, F, Cl, Br, OCF3, or CH2CH2OH, but is not limited thereto.
[0073]
[0074] In one embodiment of the present invention, X is H, C 1-6 Alkyl, C 1-6 Alkoxy, halo C 1-6 Alkyl, Hydroxy C 1-6 Alkyl, Halo C1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkinil, C 3-6 Cycloalkyl, OH, CN, F, Br, phenyl, 5- to 6-membered heterocycloalkyl or mono- or di-C 1-6 It may be an alkylamino, but is not limited thereto.
[0075]
[0076] More specifically, the above X may be H, methyl, ethyl, isopropyl, t-butyl, CF3, cyclopropyl, methoxy, hydroxyisopropyl, propenyl, ethynyl, OH, CN, F, Br, phenyl, piperidinyl, or morpholinyl, but is not limited thereto.
[0077]
[0078] In one embodiment of the present invention, the compound may be represented by any one selected from the group consisting of the following, but is not limited thereto:
[0079]
[0080]
[0081]
[0082]
[0083]
[0084]
[0085]
[0086] and .
[0087]
[0088] The compound of Formula 1 according to the present invention has an activity that increases the biological activity of at least one aryl hydrocarbon receptor (AhR). Therefore, the compound of the present invention, etc., can act or function as an activator of the aryl hydrocarbon receptor.
[0089] In some embodiments, the compounds of the present invention can specifically bind to aryl hydrocarbon receptors. More specifically, the compounds of the present invention can specifically bind to aryl hydrocarbon receptors in the skin or epithelium and can enhance the activity of aryl hydrocarbon receptors in the skin or epithelium. In some embodiments, the compounds of the present invention can degrade in the blood. That is, the compounds of the present invention can degrade in the blood and lose their ability to activate aryl hydrocarbon receptors. Therefore, the compounds of the present invention can enhance the activity of aryl hydrocarbon receptors in the skin or epithelium to strengthen or repair the skin barrier, exert antioxidant effects, and suppress hyperimmunity; however, since they degrade in the blood, they do not cause side effects in other parts of the body and do not accumulate in the body.
[0090] The compounds of the present invention are characterized by essentially including a hydroxyl group at the 3rd position of a phenyl group and additionally including an X group at the 4th position. In some embodiments, the compounds of the present invention may have a higher binding affinity to an aryl hydrocarbon receptor and / or an aryl hydrocarbon receptor activating effect compared to a compound having the same structure but not essentially including a hydroxyl group at the 3rd position. In other embodiments, the compounds of the present invention may have a higher water solubility compared to a compound having the same structure but not including a hydroxyl group at the 3rd position.
[0091] In some embodiments, the compounds of the present invention may increase the expression of skin barrier-related genes, that is, genes of proteins or RNAs that are directly or indirectly involved in the formation, maintenance, and / or strengthening of the skin barrier. Specific examples of the skin barrier-related genes include, but are not limited to, FLGN. In some embodiments, the compounds of the present invention may increase the expression of antioxidant-related genes, that is, genes of proteins or RNAs that have antioxidant or anti-inflammatory activity or protect cells from oxidative stress. Specific examples of the antioxidant-related genes include, but are not limited to, Nqo1. In some embodiments, the compounds of the present invention may alleviate or treat inflammatory reactions and / or edema of the skin, but are not limited thereto.
[0092]
[0093] Pharmaceutical composition
[0094] The compound of Formula 1 according to the present invention exhibits an activating effect on aryl hydrocarbon receptors as described above, so it can be usefully used for the prevention or treatment of skin diseases, inflammatory diseases, or autoimmune diseases.
[0095]
[0096] Accordingly, the present invention provides a composition for the prevention, improvement, and / or treatment of skin diseases, inflammatory diseases, or autoimmune diseases, comprising as an active ingredient a compound of Formula 1, a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, hydrate, solvate, polymorph, or isotope variant thereof. The composition may be a pharmaceutical composition and / or a food composition.
[0097] In addition, the present invention provides a kit for the prevention, improvement, and / or treatment of skin diseases, inflammatory diseases, or autoimmune diseases, comprising the compound of Formula 1 or the like as an active ingredient.
[0098] In addition, the present invention provides an external preparation for the prevention, improvement, and / or treatment of skin diseases, inflammatory diseases, or autoimmune diseases, comprising a compound of Formula 1 or the like as an active ingredient.
[0099] In addition, the present invention provides a method for the prevention, improvement, and / or treatment of a skin disease, an inflammatory disease, or an autoimmune disease, comprising the step of administering a compound of Formula 1 or the like to a subject who requires it. The method may further include the step of identifying a subject who requires the prevention, improvement, and / or treatment of a skin disease, an inflammatory disease, or an autoimmune disease prior to the step of administration.
[0100] In addition, the present invention provides uses for the compound of Formula 1, etc., for the prevention, improvement, and / or treatment of skin diseases, inflammatory diseases, or autoimmune diseases.
[0101] In addition, the present invention provides uses for the compound of Formula 1, etc., for the manufacture of a drug for the prevention, improvement, and / or treatment of skin diseases, inflammatory diseases, or autoimmune diseases.
[0102] In one embodiment of the present invention, the skin disease may be atopic dermatitis, but is not limited thereto.
[0103] In this specification, "prevention" refers to any act of suppressing or delaying the onset of a disease (disease) by administering a composition according to one example, "treatment" refers to any act of improving or beneficially changing the symptoms of an individual suspected of or suffering from a disease by administering a composition according to one example, and "improvement" may refer to any act of at least reducing parameters related to the state in which the disease is treated, such as the degree of symptoms, by administering a composition according to one example. In the present invention, the disease is a skin disease, an inflammatory disease, or an autoimmune disease. Furthermore, in the present invention, the prevention, improvement, and / or treatment are attributed to increasing the activity of aryl hydrocarbon receptors in cells or subjects. Accordingly, the compounds of the present invention may be particularly useful in subjects in which the expression and / or activity of aryl hydrocarbon receptors is reduced, but are not limited thereto.
[0104] Meanwhile, the pharmaceutical composition of the present invention may be formulated into an oral or parenteral administration form according to standard pharmaceutical practices. These formulations may contain, in addition to the active ingredient, pharmaceutically acceptable additives such as carriers, adjuvants, or diluents.
[0105] Suitable carriers include, for example, physiological saline, polyethylene glycol, ethanol, vegetable oil, and isopropyl myristate, and diluents include, for example, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine, but are not limited thereto. In addition, the compounds of the present invention may be dissolved in oils, propylene glycol, or other solvents commonly used in the preparation of injectable solutions. Furthermore, the compounds of the present invention may be formulated into ointments or creams for topical action.
[0106] The compounds of the present invention may be formulated into injectables by dissolving, suspending, or emulsifying the compounds in a water-soluble solvent such as ordinary saline solution or about 5% dextrose, or in a water-insoluble solvent such as synthetic fatty acid glycerides, higher fatty acid esters, or propylene glycol. The formulations of the present invention may include conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers, and preservatives.
[0107] The pharmaceutical dosage forms of the compounds of the present invention may be used alone, in combination with other pharmaceutically active compounds, as well as in a suitable combination.
[0108] The preferred dosage of the compound of the present invention varies depending on the patient's condition and body weight, the severity of the disease, the form of the drug, the route of administration, and the duration, but can be appropriately selected by those skilled in the art. However, for a desirable effect, it is preferable to administer the compound of the present invention at about 0.0001 to 100 mg / kg (body weight) per day, preferably about 0.001 to 100 mg / kg (body weight). Administration may be administered once a day or in divided doses via oral or parenteral routes. Depending on the method of administration, the composition may contain about 0.001 to 99 weight%, preferably about 0.01 to 60 weight% of the compound of the present invention.
[0109] In the present invention, "administration" means providing a specific compound of the present invention to an individual by any appropriate method. The pharmaceutical composition of the present invention may be administered to an individual by various routes. All modes of administration may be anticipated, for example, oral administration, subcutaneous injection, intraperitoneal administration, intramuscular injection, intrathecal injection, sublingual administration, buccal mucosal administration, rectal insertion, vaginal insertion, ocular administration, ear administration, nasal administration, inhalation, spray through the mouth or nose, skin administration, transdermal administration, intrauterine dura mater or intrarebroventricular injection, etc.
[0110] The subjects of administration of the composition of the present invention may be one or more mammals selected from primates such as humans and monkeys, rodents such as mice and rats, livestock such as dogs, cats, pigs, cattle, horses, sheep, goats, etc., and poultry such as chickens, ducks, geese, pheasants, quails, and turkeys, or cells, tissues, or cultures derived from these.
[0111] When the compound of the present invention is used as a food additive, the compound may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods. The amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health, or therapeutic treatment). Generally, when manufacturing food or beverages, the compound of the present invention may be added in an amount of 15% by weight or less, or 10% by weight or less, relative to the raw material. However, in the case of long-term consumption for the purpose of health and hygiene or health control, the above amount may be less than the above range, and since there are no issues regarding safety, the active ingredient may be used in an amount greater than the above range.
[0112]
[0113] There are no specific restrictions on the types of the above-mentioned foods. Examples of foods to which the above-mentioned substance may be added include meat, sausage, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and include all health functional foods in the conventional sense.
[0114] In addition to the above, the composition of the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Furthermore, the composition of the present invention may contain fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used independently or in combination. Although the proportion of these additives is not critical, it is generally selected in the range of 0.01 to 0.20 parts by weight per 100 parts by weight of the composition of the present invention.
[0115] In this specification, the term "health functional food" is synonymous with "food for special health use (FoSHU)" and refers to a food with high medical or therapeutic effects that is processed to efficiently exhibit bio-regulatory functions in addition to providing nutrition. The food may be manufactured in various forms such as tablets, capsules, powders, granules, liquids, and pills to obtain useful effects for the prevention or improvement of skin diseases, inflammatory diseases, or autoimmune diseases.
[0116]
[0117] Compounds of Formula 1 according to the present invention can induce enhancement of the activity of aryl hydrocarbon receptors. Accordingly, compounds of the present invention can increase the activity of aryl hydrocarbon receptors and exhibit preventive, corrective, and / or therapeutic activities for the aforementioned diseases.
[0118]
[0119] Cosmetic composition
[0120] The compound of Formula 1 according to the present invention can enhance the activity of aryl hydrocarbon receptors as described above, and can alleviate skin inflammation and promote skin health by increasing the expression of proteins that contribute directly or indirectly to the creation, maintenance, and strengthening of the skin barrier.
[0121] Accordingly, the present invention provides a cosmetic composition for the prevention and / or improvement of skin diseases, comprising as an active ingredient a compound of Formula 1, a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, hydrate, solvate, polymorph, or isotope variant thereof.
[0122] In addition, the present invention provides a cosmetic kit for the prevention and / or improvement of skin diseases, comprising the compound of Formula 1 or the like as an active ingredient.
[0123] In addition, the present invention provides an external agent for the prevention and / or improvement of skin diseases, comprising a compound of Formula 1 or the like as an active ingredient. The external agent may be a skin external agent.
[0124] In addition, the present invention provides a skin care method comprising the step of administering a compound of Formula 1 or the like to a subject who requires it. The method may further include the step of identifying a subject who requires skin care (e.g., improvement of skin inflammation, promotion of skin health, and / or promotion or strengthening of skin barrier formation, etc.) prior to the administration step.
[0125] In addition, the present invention provides uses for the compound of Formula 1, etc., for skin care.
[0126] In addition, the present invention provides a use for the compound of Formula 1, etc., for the preparation of a cosmetic composition for skin care.
[0127] A detailed explanation of skin diseases has been provided above, so the same description is omitted.
[0128] The formulation of the cosmetic composition according to the present invention may be in the form of a skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, mist, moisture cream, hand cream, hand lotion, foundation, essence, nourishing essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, cleansing oil, cleansing balm, body lotion, or body cleanser.
[0129] The cosmetic composition of the present invention may further include a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, high molecular weight polysaccharides, and sphingolipids.
[0130] In addition to the essential ingredients mentioned above, the cosmetic composition of the present invention may also include other ingredients commonly used in cosmetics as needed.
[0131] Other ingredients that may be added include oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, disinfectants, antioxidants, plant extracts, pH adjusters, alcohols, dyes, fragrances, blood circulation promoters, cooling agents, antiperspirants, purified water, etc.
[0132] Examples of oil components include ester oils, hydrocarbon oils, silicone oils, fluorinated oils, animal oils, and plant oils.
[0133] Meanwhile, the composition of the present invention may be provided in the form of an external preparation. The external preparation may be a skin external preparation. The skin external preparation may be in various formulations. Specific examples of formulations as skin external preparations may be any one selected from plasters, lotions, liniments, aromatic waters, aerosols, ointments, emulsions, cataplasmas, creams, and pastes.
[0134] For example, the above-mentioned topical skin preparation may include a pharmaceutically acceptable base; a carrier; an excipient; a binder comprising starch, tragacanth gum, gelatin, molasses, polyvinyl alcohol, polyvinyl ether, polyvinylpyrrolidone, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, and carboxymethyl cellulose; a grinding agent comprising agar, starch, gelatin powder, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, crystalline cellulose, calcium carbonate, sodium bicarbonate, and sodium alginate; a lubricant comprising magnesium stearate, talc, and hydrogenated vegetable oil; and a coloring agent, etc., and the carrier and excipient may include lactose, glucose, sucrose, mannitol, potato starch, corn starch, calcium carbonate, calcium phosphate, and cellulose, etc. In addition, auxiliary agents such as stabilizers, solubilizing agents, and transdermal absorption promoters, as well as additives such as fragrances and preservatives, may be further added.
[0135]
[0136] Uses for enhancing the activity of aryl hydrocarbon receptors
[0137] The present invention also provides a composition for enhancing the activity of an aryl hydrocarbon receptor, comprising as an active ingredient a compound of Formula 1, a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, hydrate, solvate, polymorph, or isotopic variant thereof. The composition may be a pharmaceutical composition, a food composition, and / or a cosmetic composition.
[0138] In addition, the present invention provides a method for enhancing the activity of an aryl hydrocarbon receptor, comprising the step of administering a compound of Formula 1 or the like to a target that requires it. The method may further include the step of identifying a target that requires enhancement of the activity of the aryl hydrocarbon receptor prior to the step of administration.
[0139] In addition, the present invention provides uses for compounds of Formula 1, etc., for the prevention or treatment of skin diseases or for enhancing the activity of aryl hydrocarbon receptors.
[0140] In addition, the present invention provides a use for the compound of Formula 1, etc., for the preparation of an activity enhancer for an aryl hydrocarbon acceptor.
[0141] The description of the composition and other terms is the same as that described above, so it is omitted.
[0142]
[0143] Manufacturing method
[0144] In addition, the present invention provides a method for preparing a compound of Formula 1, comprising the following steps:
[0145] 1) A step of obtaining a compound of formula 4A by reacting a compound of formula 5A with acetic anhydride (Ac2O);
[0146] 2) A step of obtaining a compound of formula 3A by reacting the compound of formula 4A and the compound of formula I through an amide coupling reaction;
[0147] 3) A step of obtaining a compound of formula 2A by dissolving the compound of formula 3A in THF, methanol, and water, and then hydrolyzing lithium hydroxide monohydrate; and
[0148] 4) A step of obtaining a compound of Formula 1 by reacting the compound of Formula 2A with a coupling agent:
[0149]
[0150] [Chemical Formula 5A]
[0151]
[0152]
[0153] [Chemical Formula 4A]
[0154]
[0155]
[0156] [Chemical Formula I]
[0157]
[0158]
[0159] [Chemical Formula 3A]
[0160]
[0161]
[0162] [Chemical Formula 2A]
[0163]
[0164]
[0165] [Chemical Formula 1]
[0166]
[0167] In the above formulas, A, R, X, and n are as defined in Formula 1.
[0168]
[0169] The method for preparing the compound of Chemical Formula 1 can be represented by the following reaction scheme A.
[0170] [Reaction Equation A]
[0171]
[0172]
[0173] In addition, the compound of Formula 1 according to the present invention may also be prepared according to a method of preparation comprising the following preparation steps:
[0174] a) a step of reacting a compound of formula II with a compound of formula I to obtain a compound of formula 4B;
[0175] b) a step of dissolving the compound of formula 4B above in THF, methanol, and water, and then reacting it with lithium hydroxide monohydrate to obtain the compound of formula 3B;
[0176] c) a step of reacting the compound of Formula 3B with a coupling agent to obtain a compound of Formula 2B; and
[0177] d) A step of obtaining a compound of Formula 1 by dimethylating the compound of Formula 2B using BBr3:
[0178]
[0179] [Chemical Formula II]
[0180]
[0181]
[0182] [Chemical Formula I]
[0183]
[0184]
[0185] [Chemical Formula 4B]
[0186]
[0187]
[0188] [Chemical Formula 3B]
[0189]
[0190]
[0191] [Chemical Formula 2B]
[0192]
[0193]
[0194] [Chemical Formula 1]
[0195] .
[0196] In the above formulas, A, R, X, and n are as defined in Formula 1.
[0197]
[0198] The method for preparing the compound of Chemical Formula 1 can be represented by the following reaction scheme B.
[0199]
[0200] [Reaction Equation B]
[0201]
[0202]
[0203] The present invention will be explained in more detail below through the following examples. However, the following examples are merely illustrative of the present invention, and the scope of the present invention is not limited thereto.
[0204]
[0205] [Example]
[0206] Representative Example. 1. Preparation of a novel heterocyclic compound containing an oxazinone structure (Example 31)
[0207] [Reaction Equation 1]
[0208]
[0209]
[0210] Step 1. Synthesis of intermediate 4'
[0211] Compound 5' (600 mg, 3.33 mmol) was dissolved in acetic anhydride (6.28 mL, 66.6 mmol) and stirred at 130°C for 3 hours. The reaction mixture was cooled to 70°C, water (24 mL) was added, and the mixture was stirred overnight at room temperature. The resulting solid was filtered, washed with water, and dried under high vacuum to obtain intermediate 4' (628 mg, 85%).
[0212]
[0213] Step 2. Synthesis of Intermediate 3'
[0214] Intermediate 4' (200 mg, 0.9 mmol) was dissolved in DCM (8 mL), followed by the addition of thionyl chloride (0.152 mL, 2.08 mmol) and pyridine (0.168 mL, 2.08 mmol). The mixture was stirred at room temperature for 2 hours, and the reaction mixture was subjected to vacuum distillation. The residue was dissolved in acetonitrile (8 mL), followed by the addition of methyl 2-aminobenzoate (105 mg) (Formula I'), and the mixture was stirred overnight at room temperature. The reaction was terminated by adding water, and the mixture was extracted with EtOAc. The organic layer was washed with water, dried with anhydrous MgSO4, filtered, concentrated under vacuum, and purified by silica gel column chromatography to obtain intermediate 3' (180 mg, 73%).
[0215]
[0216] Step 3. Synthesis of Intermediate 2'
[0217] Intermediate 3' (180 mg, 0.506 mmol) was dissolved in THF (6 mL), methanol (2 mL), and water (2 mL), and then lithium hydroxide monohydrate (106 mg, 2.53 mmol) was added. The reaction mixture was stirred overnight at room temperature and then concentrated under reduced pressure. The residue was dissolved in water, acidified to pH 2 by adding 1N aqueous HCl solution dropwise, and extracted with EtOAc. The organic layer was washed with water, dried with anhydrous MgSO4, filtered, and concentrated under reduced pressure to obtain intermediate 2' (145 mg, 96%).
[0218]
[0219] Step 4. Synthesis of Target Compound 1'
[0220] Intermediate 2' (125 mg, 0.418 mmol) was dissolved in DCM (4 mL), EDC HCl (120 mg, 0.626 mmol) was added, and the mixture was stirred at room temperature for 2 hours. The reaction was terminated by adding water, and the mixture was extracted with EtOAc. The organic layer was washed with a saturated aqueous NaCl solution, dried with anhydrous MgSO4, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography to obtain target compound 1 (93 mg, 79%; Example 31).
[0221] 1H NMR: DMSO-d6 (δ) 9.85(br s, 1H), 8.15(d, 1H), 7.96-7.93(m, 3H), 7.70-7.69(m, 2H), 7.64-7.59(m, 2H), 7.33(d, 1H), 3.29-3.24(m, 1H), 1.20(d, 6H)
[0222]
[0223] Representative Example. 2. Preparation of a novel heterocyclic compound containing an oxazinone structure (Example 21)
[0224] [Reaction Equation 2]
[0225]
[0226]
[0227] Step 1. Synthesis of Intermediate 4”
[0228] 3-methoxy-4-methylbenzoic acid (299 mg, 1.8 mmol) (Chemical Formula II”) was dissolved in DCM (10 mL), followed by the addition of thionyl chloride (0.263 mL, 3.6 mmol) and pyridine (0.29 mL, 3.6 mmol). The mixture was stirred at room temperature for 3 hours, and the reaction mixture was subjected to vacuum distillation. The residue was dissolved in acetonitrile (10 mL), followed by the addition of methyl 2-aminobenzoate (181 mg, 1.2 mmol) (Chemical Formula I'), and the mixture was stirred overnight at room temperature. The reaction was terminated by adding water, and the mixture was extracted with EtOAc. The organic layer was washed with water, dried with anhydrous MgSO4, filtered, concentrated under vacuum, and purified by silica gel column chromatography to obtain intermediate 4” (90 mg, 25%).
[0229]
[0230] Step 2. Synthesis of Intermediate 3”
[0231] Intermediate 4” (90 mg, 0.301 mmol) was dissolved in THF (1.8 mL), methanol (0.6 mL), and water (0.6 mL), and then lithium hydroxide monohydrate (37.8 mg, 0.902 mmol) was added. The reaction mixture was stirred overnight at room temperature and then concentrated under reduced pressure. The residue was dissolved in water, acidified to pH 2 by adding 1N aqueous HCl solution dropwise, and extracted with EtOAc. The organic layer was washed with water, dried with anhydrous MgSO4, filtered, and concentrated under reduced pressure to obtain intermediate 3 (82 mg, 96%).
[0232]
[0233] Step 3. Synthesis of Intermediate 2”
[0234] Intermediate 3” (60 mg, 0.21 mmol) was dissolved in DCM (3 mL), then EDC HCl (60.5 mg, 0.315 mmol) was added and stirred at room temperature for 2 hours. The reaction was terminated by adding water and extracted with EtOAc. The organic layer was washed with a saturated aqueous NaCl solution, dried with anhydrous MgSO4, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography to obtain intermediate 2” (45 mg, 80%).
[0235]
[0236] Step 4. Synthesis of Target Compound 1
[0237] Intermediate 2” (43 mg, 0.161 mmol) was dissolved in DCM (1 mL) and cooled to 0°C. BBr3 (1.0 M solution in DCM) (1.541 mL, 1.541 mmol) was added dropwise and stirred at room temperature for 6 hours. The reaction mixture was placed on ice to terminate the reaction and extracted with EtOAc. The organic layer was dried with anhydrous MgSO4, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography to obtain target compound 1” (10 mg, 24%, Example 21).
[0238] 1H NMR: DMSO-d6 (δ) 9.86(br s, 1H), 8.14(d, 1H), 7.96-7.93(m, 1H), 7.69-7.68(m, 2H), 7.62-7.57(m, 2H), 7.28(d, 1H), 2.21(s, 3H)
[0239]
[0240] Based on the synthesis process of reaction scheme 1 or 2 described above, the following examples were additionally synthesized.
[0241]
[0242] Example 1. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-benzo[d][1,3]oxazin-4-one
[0243] Example 1 was prepared according to the manufacturing method described in Representative Example 2.
[0244] 1H NMR: DMSO-d6 (δ) 11.08(br s, 1H), 8.17(d, 1H), 7.99-7.96(m, 1H), 7.88(s, 1H), 7.75-7.74(m, 3H), 7.68-7.65(m, 1H)
[0245]
[0246] Example 2. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)pyrrolo[3,2-d][1,3]oxazin-4(5H)-one
[0247]
[0248] Example 2 was prepared according to the manufacturing method described in Representative Example 1.
[0249] 1H NMR: DMSO-d6 (δ) 12.77 (br. s, 1H), 7.80 (s, 1H), 7.67 (q, 2H), 7.62 (s, 1H), 6.57 (s, 1H)
[0250]
[0251] Example 3. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6-methyl-4H-pyrido[3,2-d][1,3]oxazin-4-one
[0252] Example 3 was prepared according to the manufacturing method described in Representative Example 2.
[0253] 1H NMR: DMSO-d6 (δ) 11.12(br s, 1H), 8.05(d, 1H), 7.86(s, 1H), 7.82(d, 1H), 7.75-7.71(m, 2H), 2.66(s, 3H)
[0254]
[0255] Example 4. Preparation of 5-(3-hydroxy-4-(trifluoromethyl)phenyl)pyrazolo[4,3-d][1,3]oxazin-7(1H)-one
[0256] Example 4 was prepared according to the manufacturing method described in Representative Example 1.
[0257] 1H NMR (DMSO-d6): 14.67 (s, 1H), 11.07 (s, 1H), 8.45 (br. s., 1H), 7.81 (s, 1H), 7.64 - 7.75 (m, 2H)
[0258]
[0259] Example 5. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-7-methyl-4H-benzo[d][1,3]oxazin-4-one
[0260] Example 5 was prepared according to the manufacturing method described in Representative Example 2.
[0261] 1H NMR: DMSO-d6 (δ) 11.12(br s, 1H), 8.06(d, 1H), 7.86(s, 1H), 7.74-7.71(m, 2H), 7.57(s, 1H), 7.49(d, 1H), 2.50(s, 3H)
[0262]
[0263] Example 6. Preparation of 5-(3-hydroxy-4-(trifluoromethyl)phenyl)-3-methylpyrazolo[4,3-d][1,3]oxazin-7(1H)-one
[0264] Example 6 was prepared according to the manufacturing method described in Representative Example 1.
[0265] 1H NMR DMSO-d6 (δ) 14.39 (br. s, 1H), 10.99 (br. s, 1H), 7.83 (s, 1H), 7.64 - 7.74 (m, 1H), 3.33 - 3.38 (m, 3H)
[0266]
[0267] Example 7. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-pyrido[3,2-d][1,3]oxazin-4-one
[0268] Example 7 was prepared according to the manufacturing method described in Representative Example 2.
[0269] 1H NMR: DMSO-d6 (δ) 11.15(br s, 1H), 8.87(d, 1H), 8.16(d, 1H), 7.95-7.93(m, 1H), 7.88(s, 1H), 7.77-7.73(m, 2H)
[0270]
[0271] Example 8. Preparation of 5-(3-hydroxy-4-(trifluoromethyl)phenyl)-2-methyl-7H-oxazolo[5,4-d][1,3]oxazin-7-one
[0272] Example 8 was prepared according to the manufacturing method described in Representative Example 2.
[0273] 1H NMR: DMSO-d6 (δ) 11.24(br s, 1H), 7.82(s, 1H), 7.75(d, 1H), 7.70(d, 1H), 2.62(s, 3H)
[0274]
[0275] Example 9. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-7-methoxy-4H-benzo[d][1,3]oxazin-4-one
[0276] Example 9 was prepared according to the manufacturing method described in Representative Example 2.
[0277] 1H NMR: DMSO-d6 (δ) 11.14(br s, 1H), 8.08(d, 1H), 7.85(s, 1H), 7.74-7.71(m, 2H), 7.23-7.21(m, 2H), 3.96(s, 3H)
[0278]
[0279] Example 10. Preparation of 7-hydroxy-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-benzo[d][1,3]oxazin-4-one
[0280] Example 10 was prepared according to the manufacturing method described in Representative Example 2.
[0281] 1H NMR: DMSO-d6 (δ) 11.13(br s, 2H), 8.01(d, 1H), 7.86(s, 1H), 7.73-7.70(m, 2H), 7.05(d, 1H), 6.99(s, 1H)
[0282]
[0283] Example 11. Preparation of 5-(3-hydroxy-4-(trifluoromethyl)phenyl)-3-methylpyrazolo[4,3-d][1,3]oxazin-7(1H)-one
[0284] Example 11 was prepared according to the manufacturing method described in Representative Example 1.
[0285] 1H NMR: DMSO-d6 (δ) 11.03 (br. s, 1H), 10.35 (br. s, 1H), 7.94 (d, 1H), 7.87 (s, 1H), 7.74 (d, 1H), 7.60 (d, 1H), 7.47 (t, 1H), 7.38 (d, 1H)
[0286]
[0287] Example 12. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6-methoxy-4H-benzo[d][1,3]oxazin-4-one
[0288] Example 12 was prepared according to the manufacturing method described in Representative Example 1.
[0289] 1H NMR: DMSO-d6 (δ) 11.06 (br. s, 1H), 7.85 (s, 1H), 7.69 - 7.75 (m, 3H), 7.54 - 7.60 (m, 2H), 3.93 (s, 3H)
[0290]
[0291] Example 13. Preparation of 6-hydroxy-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-benzo[d][1,3]oxazin-4-one
[0292] Example 13 was prepared according to the manufacturing method described in Representative Example 1.
[0293] 1H NMR: DMSO-d6 (δ) 11.03 (br. s, 1H), 10.57 (br. s, 1H), 7.83 (s, 1H), 7.66 - 7.74 (m, 2H), 7.63 (d, 1H), 7.44 (s, 1H), 7.39 (d, 1H)
[0294]
[0295] Example 14. Preparation of 2-hydroxy-4-(4-oxo-4H-benzo[d][1,3]oxazin-2-yl)benzonitrile
[0296] Example 14 was prepared according to the manufacturing method described in Representative Example 2.
[0297] 1H NMR: DMSO-d6 (δ) 11.72(br s, 1H), 8.17(d, 1H), 7.99-7.96(m, 2H), 7.83-7.82(m, 2H), 7.75(d, 1H), 7.71-7.66(m, 2H)
[0298]
[0299] Example 15. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-7-(trifluoromethyl)-4H-benzo[d][1,3]oxazin-4-one
[0300] Example 15 was prepared according to the manufacturing method described in Representative Example 2.
[0301] 1H NMR: DMSO-d6 (δ) 11.16(br s, 1H), 8.36(d, 1H), 8.07(s, 1H), 7.97(d, 1H), 7.88(s, 1H), 7.79-7.75(m, 2H)
[0302]
[0303] Example 16. Preparation of 22-(3-hydroxy-4-(trifluoromethyl)phenyl)-8-methyl-4H-benzo[d][1,3]oxazin-4-one
[0304] Example 16 was prepared according to the manufacturing method described in Representative Example 1.
[0305] 1H NMR: DMSO-d6 (δ) 11.04 (s, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.87 (s, 1H), 7.81 (d, J = 7.3 Hz, 1H), 7.72 (dd, J = 11.4, 8.7 Hz, 2H), 7.51 (t, J = 7.5 Hz, 1H), 2.57 (s, 3H).
[0306]
[0307] Example 17. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-7,8-dimethyl-4H-benzo[d][1,3]oxazin-4-one
[0308] Example 17 was prepared according to the manufacturing method described in Representative Example 1.
[0309] 1H NMR: DMSO-d6 (δ) 11.02 (s, 1H), 7.87 (t, J = 3.9 Hz, 2H), 7.70 (dd, J = 11.7, 8.5 Hz, 2H), 7.42 (d, J = 7.8 Hz, 1H), 2.51 (s, 3H), 2.39 (s, 3H).
[0310]
[0311] Example 18. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6,7-dimethyl-4H-benzo[d][1,3]oxazin-4-one
[0312] Example 18 was prepared according to the manufacturing method described in Representative Example 1.
[0313] 1H-NMR: DMSO-d6 (δ) 11.05 (s, 1H), 7.88 (s, 1H), 7.80 (s, 1H), 7.67 (m, 2H), 7.51 (s, 1H), 2.37 (s, 3H), 2.34 (s, 3H)
[0314]
[0315] Example 19. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6-methyl-4H-benzo[d][1,3]oxazin-4-one
[0316] Example 19 was prepared according to the manufacturing method described in Representative Example 1.
[0317] 1H NMR: DMSO-d6 (δ) 11.04 (s, 1H), 7.94 (s, 1H), 7.82 (s, 1H), 7.75 (dd, 1H), 7.68 (s, 2H), 7.60 (d, 1H), 2.44 (s, 3H).
[0318]
[0319] Example 20. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-8-(trifluoromethyl)-4H-benzo[d][1,3]oxazin-4-one
[0320] Example 20 was prepared according to the manufacturing method described in Representative Example 2.
[0321] 1H NMR: DMSO-d6 (δ) 8.43(d, 1H), 8.31(d, 1H), 7.89-7.85(m, 1H), 7.79-7.76(m, 2H), 7.72-7.68(m, 1H)
[0322]
[0323] Example 21. Preparation of 2-(3-hydroxy-4-methylphenyl)-4H-benzo[d][1,3]oxazin-4-one
[0324] Example 21 was prepared according to the manufacturing method described in Representative Example 2.
[0325] 1H NMR: DMSO-d6 (δ) 9.86(br s, 1H), 8.14(d, 1H), 7.96-7.93(m, 1H), 7.69-7.68(m, 2H), 7.62-7.57(m, 2H), 7.28(d, 1H), 2.21(s, 3H)
[0326]
[0327] Example 22. Preparation of 2-(4-(tert-butyl)-3-hydroxyphenyl)-4H-benzo[d][1,3]oxazin-4-one
[0328] Example 22 was prepared according to the manufacturing method described in Representative Example 2.
[0329] 1H NMR: DMSO-d6 (δ) 9.90(br s, 1H), 8.15(d, 1H), 7.96-7.93(m, 1H), 7.70-7.68(m, 2H), 7.63-7.58(m, 2H), 7.36(d, 1H), 1.38(s, 9H)
[0330]
[0331] Example 23. Preparation of 6,8-difluoro-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-benzo[d][1,3]oxazin-4-one
[0332] Example 23 was prepared according to the manufacturing method described in Representative Example 1.
[0333] 1H NMR: DMSO-d6 (δ) 11.07 (s, 1H), 7.99 (td, J = 9.7, 2.6 Hz, 1H), 7.86 (s, 1H), 7.79 (dt, J = 7.8, 1.4 Hz, 1H), 7.70 (dd, J = 14.0, 8.5 Hz, 2H).
[0334]
[0335] Example 24. Preparation of 6,7-dichloro-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-benzo[d][1,3]oxazin-4-one
[0336] Example 24 was prepared according to the manufacturing method described in Representative Example 1.
[0337] 1H NMR: DMSO-d6 (δ) 11.12 (s, 1H), 8.30 (s, 1H), 8.05 (s, 1H), 7.82 (s, 1H), 7.71 (dd, J = 14.4, 8.5 Hz, 2H).
[0338]
[0339] Example 25. Preparation of 6-fluoro-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-8-methyl-4H-benzo[d][1,3]oxazin-4-one
[0340] Example 25 was prepared according to the manufacturing method described in Representative Example 1.
[0341] 1H NMR: DMSO-d6 (δ) 11.12 (s, 1H), 8.30 (s, 1H), 8.05 (s, 1H), 7.82 (s, 1H), 7.71 (dd, 2H).
[0342]
[0343] Example 26. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-8-methoxy-4H-benzo[d][1,3]oxazin-4-one
[0344] Example 26 was prepared according to the manufacturing method described in Representative Example 1.
[0345] 1H NMR: DMSO-d6 (δ) 11.13(br s, 1H), 7.89(s, 1H), 7.74-7.69(m, 3H), 7.61-7.56(m, 2H), 3.98(s, 3H)
[0346]
[0347] Example 27. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6-methoxy-4H-pyrido[3,2-d][1,3]oxazin-4-one
[0348] Example 27 was prepared according to the manufacturing method described in Representative Example 1.
[0349] 1H NMR: DMSO-d6 (δ) 11.09(br s, 1H), 8.06(d, 1H), 7.82(s, 1H), 7.73-7.68(m, 2H), 7.40(d, 1H), 3.99(s, 3H)
[0350]
[0351] Example 28. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6-(trifluoromethyl)-4H-benzo[d][1,3]oxazin-4-one
[0352] Example 28 was prepared according to the manufacturing method described in Representative Example 1.
[0353] 1H NMR: DMSO-d6 (δ) 11.17 (br. s, 1H), 8.41 (s, 1H), 8.30 (d, 1H), 7.95 (d, 1H), 7.91 (s, 1H), 7.78 (s, 2H)
[0354]
[0355] Example 29. Preparation of 2-(4-(tert-butyl)-3-hydroxyphenyl)-6-hydroxy-4H-benzo[d][1,3]oxazin-4-one
[0356] Example 29 was prepared according to the manufacturing method described in Representative Example 2.
[0357] 1H NMR: DMSO-d6 (δ) 10.46(br s, 1H), 9.84(s, 1H), 7.65(s, 1H), 7.57(d, 1H), 7.53(d, 1H), 7.42(s, 1H), 7.37-7.33(m, 2H), 1.38(s, 9H)
[0358]
[0359] Example 30. Preparation of 2-(4-(tert-butyl)-3-hydroxyphenyl)-8-methyl-4H-benzo[d][1,3]oxazin-4-one
[0360] Example 30 was prepared according to the manufacturing method described in Representative Example 2.
[0361] 1H NMR: DMSO-d6 (δ) 9.89(br s, 1H), 7.98(d, 1H), 7.81(d, 1H), 7.71(s, 1H), 7.60(d, 1H), 7.51-7.48(m, 1H), 7.36(d, 1H), 2.70(s, 1H), 1.39(s, 9H)
[0362]
[0363] Example 31. Preparation of 2-(3-hydroxy-4-isopropylphenyl)-4H-benzo[d][1,3]oxazin-4-one
[0364] Example 31 was prepared according to the manufacturing method described in Representative Example 1.
[0365] 1H NMR: DMSO-d6 (δ) 9.85(br s, 1H), 8.15(d, 1H), 7.96-7.93(m, 3H), 7.70-7.69(m, 2H), 7.64-7.59(m, 2H), 7.33(d, 1H), 3.29-3.24(m, 1H), 1.20(d, 6H)
[0366]
[0367] Example 32. Preparation of 2-(3-hydroxy-4-isopropylphenyl)-6-methoxy-4H-benzo[d][1,3]oxazin-4-one
[0368] Example 32 was prepared according to the manufacturing method described in Representative Example 1.
[0369] 1H NMR: DMSO-d6 (δ) 9.82(br s, 1H), 7.65-7.64(m, 2H), 7.59(d, 1H), 7.54-7.52(m, 2H), 7.32(d, 1H), 3.91(s, 1H), 3.28-3.24(m, 1H), 1.20(d, 6H)
[0370]
[0371] Example 33. Preparation of 2-(3-hydroxy-4-isopropylphenyl)-8-methyl-4H-benzo[d][1,3]oxazin-4-one
[0372] Example 33 was prepared according to the manufacturing method described in Representative Example 1.
[0373] 1H NMR: DMSO-d6 (δ) 9.84(br s, 1H), 7.97(d, 1H), 7.81(d, 1H), 7.71(s, 1H), 7.65(d, 1H), 7.50-7.47(m, 1H), 7.34(d, 1H), 3.29-3.24(m, 1H), 2.59(s, 3H), 1.20(d, 6H)
[0374]
[0375] Example 34. Preparation of 2-(3-hydroxy-4-methylphenyl)-8-methyl-4H-benzo[d][1,3]oxazin-4-one
[0376] Example 34 was prepared according to the manufacturing method described in Representative Example 2.
[0377] 1H NMR: DMSO-d6 (δ) 9.85 (s, 1H), 7.97 (d, 1H), 7.81 (d, 1H), 7.70 (s, 1H), 7.60 (d, 1H), 7.45 - 7.53 (m,1H), 7.29 (d, 1H), 2.60 (s, 3H), 2.22 (s, 3H)
[0378]
[0379] Example 35. Preparation of 6-hydroxy-2-(3-hydroxy-4-methylphenyl)-4H-benzo[d][1,3]oxazin-4-one
[0380] Example 35 was prepared according to the manufacturing method described in Representative Example 2.
[0381] 1H NMR: DMSO-d6 (δ) 10.43 (br. s, 1H), 9.79 (br. s, 1H), 7.62 (s, 1H), 7.56 (d, 1H), 7.51 (d, 1H), 7.41 (s, 1H), 7.36 (d, 1H), 7.24 (d, 1H), 2.20 (s, 3H)
[0382]
[0383] Example 36. Preparation of 6,7-difluoro-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-benzo[d][1,3]oxazin-4-one
[0384] Example 36 was prepared according to the manufacturing method described in Representative Example 1.
[0385] 1H NMR: DMSO-d6 (δ) 8.19 (dd, 1H), 7.88 (dd, 1H), 7.80 (s, 1H), 7.69 (dd, 2H).
[0386]
[0387] Example 37. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6,7,8-trimethoxy-4H-benzo[d][1,3]oxazin-4-one
[0388] Example 37 was prepared according to the manufacturing method described in Representative Example 1.
[0389] 1H NMR: DMSO-d6 (δ) 11.11 (br. s, 1H), 7.88 (s, 1H), 7.66 - 7.78 (m, 2H), 7.41 (s, 1H), 4.10 (s, 3H), 3.94 (s, 3H), 3.95 (s, 3H)
[0390]
[0391] Example 38. Preparation of 2-(4-(tert-butyl)-3-hydroxyphenyl)-6-methoxy-4H-pyrido[3,2-d][1,3]oxazin-4-one
[0392] Example 38 was prepared according to the manufacturing method described in Representative Example 2.
[0393] 1H NMR: DMSO-d6 (δ) 9.91(s, 1H), 8.02(d, 1H), 7.65(d, 1H), 7.55-7.53(m, 1H), 7.38(d, 1H), 7.34(d, 1H), 3.98(s, 3H), 1.38(s, 9H)
[0394]
[0395] Example 39. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6,7-dimethoxy-4H-benzo[d][1,3]oxazin-4-one
[0396] Example 39 was prepared according to the manufacturing method described in Representative Example 1.
[0397] 1H NMR: DMSO-d6 (δ) 11.10 (s, 1H), 7.84 (s, 1H), 7.73 (dd, 2H), 7.50 (s, 1H), 7.26 (s, 1H), 3.99 (s, 3H), 3.93 (s, 3H)
[0398]
[0399] Example 40. Preparation of 6-bromo-2-(4-(tert-butyl)-3-hydroxyphenyl)-8-methyl-4H-benzo[d][1,3]oxazin-4-one
[0400] Example 40 was prepared according to the manufacturing method described in Representative Example 2.
[0401] 1H NMR: DMSO-d6 (δ) 9.89(s, 1H), 8.04(d, 1H), 8.01(d, 1H), 7.69(d, 1H), 7.59-7.57(m, 1H), 7.35(d, 1H), 2.57(s, 3H), 1.38(s, 9H)
[0402]
[0403] Example 41. Preparation of 7-chloro-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-pyrido[3,2-d][1,3]oxazin-4-one
[0404] Example 41 was prepared according to the manufacturing method described in Representative Example 1.
[0405] 1H NMR: DMSO-d6 (δ) 11.19 (s, 1H), 8.91 (d, 1H), 8.41 (d, 1H), 7.87 (s, 1H), 7.71 - 7.82 (m, 2H)
[0406]
[0407] Example 42. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-pyrido[2,3-d][1,3]oxazin-4-one
[0408] Example 42 was prepared according to the manufacturing method described in Representative Example 1.
[0409] 1H NMR: DMSO-d6 (δ) 11.15 (s, 1H), 8.99 (q, 1H), 8.52 (dd, 1H), 7.88 (s, 1H), 7.74 (s, 2H), 7.63 (q, 1H)
[0410]
[0411] Example 43. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-thieno[2,3-d][1,3]oxazin-4-one
[0412] Example 43 was prepared according to the manufacturing method described in Representative Example 1.
[0413] 1H NMR: DMSO-d6 (δ) 11.1 (s, 1H), 7.84 (s, 1H), 7.80 (d, 1H), 7.75 (m, 2H), 7.56 (d, 1H)
[0414]
[0415] Example 44. Preparation of 5-(3-hydroxy-4-(trifluoromethyl)phenyl)-7H-thiazolo[4,5-d][1,3]oxazin-7-one
[0416] Example 44 was prepared according to the manufacturing method described in Representative Example 1.
[0417] 1H NMR: DMSO-d6 (δ) 11.2 (s, 1H), 9.80 (s, 1H), 7.90 (s, 1H), 7.78 (s, 2H).
[0418]
[0419] Example 45. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-7-methyl-4H-thieno[3,2-d][1,3]oxazin-4-one
[0420] Example 45 was prepared according to the manufacturing method described in Representative Example 1.
[0421] 1H NMR: DMSO-d6 (δ) 11.2 (s, 1H), 8.12 (d, 1H), 7.89 (s, 1H), 7.76 (m, 2H), 2.34 (d, 3H).
[0422]
[0423] Example 46. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6-methyl-4H-thieno[2,3-d][1,3]oxazin-4-one
[0424] Example 46 was prepared according to the manufacturing method described in Representative Example 1.
[0425] 1H NMR: DMSO-d6 (δ) 11.1 (s, 1H), 7.80 (s, 1H), 7.72 (m, 2H), 7.26 (d, 1H), 2.57 (s, 3H).
[0426]
[0427] Example 47. Preparation of 2-(3-hydroxy-4-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one
[0428] Example 47 was prepared according to the manufacturing method described in Representative Example 2.
[0429] 1H NMR: DMSO-d6 (δ) 9.59(s, 1H), 8.13-8.12(m, 1H), 7.94-7.91(m, 1H), 7.68-7.65(m, 3H), 7.59-7.56(m, 1H), 7.11(d, 1H), 3.87(s, 3H)
[0430]
[0431] Example 48.2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6-methoxy-8-methyl-4H-benzo[d][1,3]oxazin-4-one Preparation
[0432] Example 48 was prepared according to the manufacturing method described in Representative Example 1.
[0433] 1H NMR: DMSO-d6 (δ) 11.06 (br. s, 1H), 7.88 (s, 1H), 7.69 - 7.77 (m, 2H), 7.47 (dd, 1H), 7.42 (d, 1H), 3.90 (s, 3H), 2.59 (s, 3H)
[0434]
[0435] Example 49. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-benzofuro[3,2-d][1,3]oxazin-4-one
[0436] Example 49 was prepared according to the manufacturing method described in Representative Example 1.
[0437] 1H NMR: DMSO-d6 (δ) 11.19 (s, 1H), 8.13 (d, 1H), 7.96 (d, 1H), 7.93 (s, 1H), 7.76 - 7.84 (m, 3H), 7.58 - 7.66 (m, 1H)
[0438]
[0439] Example 50. Preparation of 7-hydroxy-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6-methoxy-4H-benzo[d][1,3]oxazin-4-one
[0440] Example 50 was prepared according to the manufacturing method described in Representative Example 1.
[0441] 1H NMR: DMSO-d6 (δ) 10.87 (s, 1H), 10.27 (s, 1H), 7.66 (s, 1H), 7.59 (d, 1H), 7.44 (s, 1H), 7.25 (d, 1H), 6.99 (s, 1H), 3.88 (s, 3H)
[0442]
[0443] Example 51. Preparation of 6-ethoxy-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-benzo[d][1,3]oxazin-4-one
[0444] Example 51 was prepared according to the manufacturing method described in Representative Example 1.
[0445] 1H NMR: DMSO-d6 (δ) 11.03 (s, 1H), 7.81 (s, 1H), 7.64-7.70 (m, 3H), 7.51 (td, 2H), 4.16 (q, 2H), 1.34 (t, 3H).
[0446]
[0447] Example 52. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6-(trifluoromethoxy)-4H-benzo[d][1,3]oxazin-4-one
[0448] Example 52 was prepared according to the manufacturing method described in Representative Example 1.
[0449] 1H NMR: DMSO-d6 (δ) 11.03 (s, 1H), 7.81 (s, 1H), 7.64-7.70 (m, 3H), 7.51 (td, 2H), 4.16 (q, 2H), 1.34 (t, 3H)
[0450]
[0451] Example 53. Preparation of 2-(4-ethyl-3-hydroxyphenyl)-4H-benzo[d][1,3]oxazin-4-one
[0452] Example 53 was prepared according to the manufacturing method described in Representative Example 1.
[0453] 1H NMR: DMSO-d6 (δ) 9.86 (br s, 1H), 8.15-8.14 (m, 1H), 7.96-7.93 (m, 1H), 7.70-7.68 (m, 2H), 7.63-7.59 (m, 2H), 7.29 (d, 1H), 2.63(q, 2H), 1.17(t, 3H)
[0454]
[0455] Example 54. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-pyrazino[2,3-d][1,3]oxazin-4-one
[0456] Example 54 was prepared according to the manufacturing method described in Representative Example 1.
[0457] 1H NMR: DMSO-d6 (δ) 11.21 (s, 1H), 9.08 (d, 1H), 8.92 (d, 1H), 7.93 (s, 1H), 7.80 (s, 2H)
[0458]
[0459] Example 55. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-furo[3,2-d][1,3]oxazin-4-one
[0460] Example 55 was prepared according to the manufacturing method described in Representative Example 1.
[0461] 1H NMR: DMSO-d6 (δ) 11.09 (s, 1H), 8.42 (d, 1H), 7.78 (s, 1H), 7.67 (q, 2H), 7.16 (d, 1H).
[0462]
[0463] Example 56. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6,8-dimethoxy-4H-benzo[d][1,3]oxazin-4-one
[0464] Example 56 was prepared according to the manufacturing method described in Representative Example 1.
[0465] 1H NMR: DMSO-d6 (δ) 11.02 (s, 1H), 7.82 (s, 1H), 7.62-7.69 (m, 2H), 7.09 (dd, 2H), 3.92 (s, 3H), 3.87 (s, 3H)
[0466]
[0467] Example 57. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-thieno[3,2-d][1,3]oxazin-4-one
[0468] Example 57 was prepared according to the manufacturing method described in Representative Example 1.
[0469] 1H NMR: DMSO-d6 (δ) 11.1 (s, 1H), 8.46 (d, 1H), 7.87 (s, 1H), 7.75 (t, 2H), 7.56 (d, 1H).
[0470]
[0471] Example 58. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-4H-benzo[4,5]thieno[2,3-d][1,3]oxazin-4-one
[0472] Example 58 was prepared according to the manufacturing method described in Representative Example 1.
[0473] 1H NMR: DMSO-d6 (δ) 11.07 (s, 1H), 7.77 (s, 1H), 7.70 (d, 1H), 7.65 (d, 1H), 2.76 (m, 4H), 1.82 (m, 4H).
[0474]
[0475] Example 59. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6-phenyl-4H-thieno[2,3-d][1,3]oxazin-4-one
[0476] Example 59 was prepared according to the manufacturing method described in Representative Example 1.
[0477] 1H NMR: DMSO-d6 (δ) 11.12 (s, 1H), 7.98 (s, 1H), 7.83 (m, 3H), 7.71 (m, 2H), 7.50 (m, 2H), 7.43 (m, 2H).
[0478]
[0479] Example 60. Preparation of 2-(4-cyclopropyl-3-hydroxyphenyl)-4H-benzo[d][1,3]oxazin-4-one
[0480] Example 60 was prepared according to the manufacturing method described in Representative Example 2.
[0481] 1H NMR: DMSO-d6 (δ) 9.91(s, 1H), 8.14-8.13(m, 1H), 7.95-7.92(m, 1H), 7.68-7.67(m, 2H), 7.62-7.55(m, 2H), 6.92(d, 1H), 2.22-2.16(m, 1H), 1.00-0.96(m, 2H), 0.74-0.71(m, 2H)
[0482]
[0483] Example 61. Preparation of 2-(4-bromo-3-hydroxyphenyl)-4H-benzo[d][1,3]oxazin-4-one
[0484] Example 61 was prepared according to the manufacturing method described in Representative Example 2.
[0485] 1H NMR: DMSO-d6 (δ) 9.93(s, 1H), 8.17-8.15(m, 1H), 7.98-7.94(m, 1H), 7.72(d, 1H), 7.66-7.62(m, 3H), 7.42-7.39(m, 1H), 7.06-7.04(m, 1H)
[0486]
[0487] Example 62. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-5-methyl-4H-thieno[2,3-d][1,3]oxazin-4-one
[0488] Example 62 was prepared according to the manufacturing method described in Representative Example 1.
[0489] 1H NMR: DMSO-d6 (δ) 11.10 (s, 1H), 7.81 (s, 1H), 7.72 (m, 2H), 7.39 (d, 1H), 2.46 (d, 3H).
[0490]
[0491] Example 63. Preparation of 6-ethyl-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-thieno[2,3-d][1,3]oxazin-4-one
[0492] Example 63 was prepared according to the manufacturing method described in Representative Example 1.
[0493] 1H NMR: DMSO-d6 (δ) 11.10 (s, 1H), 7.79 (s, 1H), 7.71 (m, 2H), 7.27 (m, 1H), 2.93 (q, 2H), 1.31 (t, 3H).
[0494]
[0495] Example 64. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-5,6-dimethyl-4H-thieno[2,3-d][1,3]oxazin-4-one
[0496] Example 64 was prepared according to the manufacturing method described in Representative Example 1.
[0497] 1H NMR: DMSO-d6 (δ) 11.10 (s, 1H), 7.80 (d, 1H), 7.71 (m, 2H), 2.43 (d, 3H), 2.38 (d, 3H).
[0498]
[0499] Example 65. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4H-thieno[2,3-d][1,3]oxazin-4-one
[0500] Example 65 was prepared according to the manufacturing method described in Representative Example 1.
[0501] 1H NMR: DMSO-d6 (δ) 11.18 (s, 1H), 8.46 (s, 1H), 7.84 (s, 1H), 7.74 (m, 2H).
[0502]
[0503] Example 66. Preparation of 2-(2-hydroxy-[1,1'-biphenyl]-4-yl)-4H-benzo[d][1,3]oxazin-4-one
[0504] Example 66 was prepared according to the manufacturing method described in Representative Example 2.
[0505] 1H NMR: DMSO-d6 (δ) 10.16(br s, 1H), 8.18-8.16(m, 1H), 7.98-7.95(m, 1H), 7.86(d, 1H), 7.75-7.72(m, 2H), 7.65-7.62(m, 3H), 7.50(d, 1H), 7.46-7.43(m, 2H), 7.38-7.35(m, 1H)
[0506]
[0507] Example 67. Preparation of 2-(6-hydroxy-5-(trifluoromethyl)pyridin-2-yl)-4H-benzo[d][1,3]oxazin-4-one
[0508] Example 67 was prepared according to the manufacturing method described in Representative Example 2.
[0509] 1H NMR: DMSO-d6 (δ) 13.05 (br s, 0.4H), 12.40 (br s, 0.6H), 8.20-8.17 (m, 2H), 8.03-8.00 (m, 1H), 7.78 (d, 1H), 7.73-7.70 (m, 1H), 7.34(br s, 1H)
[0510]
[0511] Example 68. Preparation of 2-(4-fluoro-3-hydroxyphenyl)-4H-benzo[d][1,3]oxazin-4-one
[0512] Example 68 was prepared according to the manufacturing method described in Representative Example 1.
[0513] 1H NMR: DMSO-d6 (δ) 10.41 (s, 1H), 8.11 (dd, 1H), 7.89-7.93 (m, 1H), 7.79 (dd, 1H), 7.66 (d, 1H), 7.57-7.64 (m, 2H), 7.32 (dd, 1H).
[0514]
[0515] Example 69. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6,8-dimethyl-4H-benzo[d][1,3]oxazin-4-one
[0516] Example 69 was prepared according to the manufacturing method described in Representative Example 1.
[0517] 1H NMR: DMSO-d6 (δ) 11.10(br s, 1H), 7.88(s, 1H), 7.81(s, 1H), 7.75-7.71(m, 2H), 7.68(s, 1H), 2.57(s, 3H), 2.43(s, 3H)
[0518]
[0519] Example 70. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6,7-dihydro-4H,5H-cyclopenta[4,5]thieno[2,3-d][1,3]oxazin-4-one
[0520] Example 70 was prepared according to the manufacturing method described in Representative Example 1.
[0521] 1H NMR: DMSO-d6 (δ) 11.15(br s, 1H), 7.80(s, 1H), 7.72-7.65(m, 2H), 3.00(t, 2H), 2.94(t, 2H), 2.47-2.41(m, 2H)
[0522]
[0523] Example 71.2 Preparation of -(3-hydroxy-4-(trifluoromethyl)phenyl)-6-isopropoxy-4H-benzo[d][1,3]oxazin-4-one
[0524] Example 71 was prepared according to the manufacturing method described in Representative Example 1.
[0525] 1H NMR: DMSO-d6 (δ) 11.05 (br. s, 1H), 7.85 (s, 1H), 7.67 - 7.76 (m, 3H), 7.51 - 7.58 (m, 2H), 4.84 (td, 1H), 1.31 - 1.37 (m,6H)
[0526]
[0527] Example 72. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-4H-pyrido[4',3':4,5]thieno[2,3-d][1,3]oxazin-4-one
[0528] Example 72 was prepared according to the manufacturing method described in Representative Example 1.
[0529] 1H NMR: DMSO-d6 (δ) 11.13 (s, 1H), 7.82 (s, 1H), 7.74 (m, 2H), 4.98 (m, 2H), 3.97 (m, 2H), 3.06 (m, 2H).
[0530]
[0531] Example 73. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-4H-pyrido[4',3':4,5]thieno[2,3-d][1,3]oxazin-4-one
[0532] Example 73 was prepared according to the manufacturing method described in Representative Example 1.
[0533] 1H NMR: DMSO-d6 (δ) 11.10 (s, 1H), 7.82 (s, 1H), 7.74 (m, 2H), 4.66 (br s, 2H), 3.68 (t, 2H), 3.92 (t, 2H), 1.44 (s, 9H).
[0534]
[0535] Example 74. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6,7-dihydro-4H,5H-pyrano[3',2':4,5]thieno[2,3-d][1,3]oxazin-4-one
[0536] Example 74 was prepared according to the manufacturing method described in Representative Example 1.
[0537] 1H NMR: DMSO-d6 (δ) 11.04 (s, 1H), 7.75 (s, 1H), 7.70 (m, 1H), 7.63 (m, 1H), 4.38 (t, 2H), 2.82 (t, 2H), 2.05 (m, 2H).
[0538]
[0539] Example 75. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-5,8-dihydro-4H,6H-pyrano[4',3':4,5]thieno[2,3-d][1,3]oxazin-4-one
[0540] Example 75 was prepared according to the manufacturing method described in Representative Example 1.
[0541] 1H NMR: DMSO-d6 (δ) 11.08 (s, 1H), 7.81 (s, 1H), 7.70 (m, 2H), 4.80 (br s, 2H), 3.96 (t, 2H), 2.92 (t, 2H)
[0542]
[0543] Example 76. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-5,8-dihydro-4H,6H-thiopyrano[4',3':4,5]thieno[2,3-d][1,3]oxazin-4-one
[0544] Example 76 was prepared according to the manufacturing method described in Representative Example 1.
[0545] 1H NMR: DMSO-d6 (δ) 11.07 (s, 1H), 7.79 (s, 1H), 7.70 (m, 2H), 3.95 (s, 2H), 3.12 (t, 2H), 2.99 (t, 2H).
[0546]
[0547] Example 77. Preparation of 2-(4-ethynyl-3-hydroxyphenyl)-4H-benzo[d][1,3]oxazin-4-one
[0548] Example 77 was prepared from the compound of Example 61 according to the following manufacturing method.
[0549] Step 1. Synthesis of Intermediate 1
[0550] A solution of Example 61 (50 mg, 0.157 mmol), tetrakis(triphenylphosphine)palladium (0) (18.16 mg, 0.016 mmol), ethynyltrimethylsilane (0.065 mL, 0.472 mmol), and copper(I) iodide (8.98 mg, 0.047 mmol) dissolved in THF (1.0 mL) was stirred overnight at 50 °C. After cooling the reaction mixture to room temperature, EtOAc and water were added. The organic layer was dried with anhydrous MgSO4, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography to obtain intermediate 1 (9 mg, 17%).
[0551]
[0552] Step 2. Synthesis of the Title Compound
[0553] Intermediate 1 (9 mg, 0.027 mmol) was dissolved in THF (0.2 mL), then Tetrabutylammonium fluoride 1.0 M solution in THF (0.054 mL) was added and stirred at room temperature for 2 hours. The reaction was terminated by adding water, and the mixture was extracted with EtOAc. The organic layer was dried with anhydrous MgSO4, filtered, and concentrated under reduced pressure, after which the title compound (2 mg, 28%) was obtained by silica gel column chromatography.
[0554] 1H NMR: DMSO-d6 (δ) 10.59(br s, 1H), 8.17-8.15(m, 1H), 7.97-7.94(m, 1H), 7.75(s, 1H), 7.71(d, 1H), 7.65-7.60(m, 2H), 7.51(d, 1H), 4.42(s, 1H)
[0555]
[0556] Example 78. Preparation of 2-(3-hydroxy-4-isopropylphenyl)-4H-thieno[2,3-d][1,3]oxazin-4-one
[0557] Example 78 was prepared according to the manufacturing method described in Representative Example 1.
[0558] 1H NMR: DMSO-d6 (δ) 9.86(s, 1H), 7.70(d, 1H), 7.64(d, 1H), 7.62-7.60(m, 1H), 7.50(d, 1H), 7.33(d, 1H), 3.29-3.24(m, 1H), 1.20(d, 6H)
[0559]
[0560] Example 79. Preparation of 2-(3-hydroxy-4-isopropylphenyl)-5-(trifluoromethyl)-4H-thieno[2,3-d][1,3]oxazin-4-one
[0561] Example 79 was prepared according to the manufacturing method described in Representative Example 1.
[0562] 1H NMR: DMSO-d6 (δ) 9.91(s, 1H), 8.38(s, 1H), 7.65-7.62(m, 2H), 7.35(d, 1H), 3.30-3.24(m, 1H), 1.20(d, 6H)
[0563]
[0564] Example 80. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-thieno[3,4-d][1,3]oxazin-4-one
[0565] Example 80 was prepared according to the manufacturing method described in Representative Example 1.
[0566] 1H NMR: DMSO-d6 (δ) 11.08(br s, 1H), 8.84(d, 1H), 8.04(d, 1H), 7.81(s, 1H), 7.72-7.66(m, 2H)
[0567]
[0568] Example 81. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-5-methyl-4H-thieno[3,4-d][1,3]oxazin-4-one
[0569] Example 81 was prepared according to the manufacturing method described in Representative Example 1.
[0570] 1H NMR: DMSO-d6 (δ) 11.07(br s, 1H), 7.79(s, 1H), 7.73(s, 1H), 7.69(d, 1H), 7.65(d, 1H), 2.87(s, 3H)
[0571]
[0572] Example 82. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-7-methyl-4H-thieno[3,4-d][1,3]oxazin-4-one
[0573] Example 82 was prepared according to the manufacturing method described in Representative Example 1.
[0574] 1H NMR: DMSO-d6 (δ) 11.04(br s, 1H), 8.62(s, 1H), 7.84(s, 1H), 7.72-7.68(m, 2H), 2.66(s, 3H)
[0575]
[0576] Example 83. Preparation of 2-(3-hydroxy-4-(prop-1-en-2-yl)phenyl)-4H-benzo[d][1,3]oxazin-4-one
[0577] Example 83 was prepared according to the manufacturing method described in Representative Example 2.
[0578] 1H NMR: DMSO-d6 (δ) 10.03(s, 1H), 8.15(d, 1H), 7.97-7.94(m, 1H), 7.73-7.69(m, 2H), 7.63-7.61(m, 2H), 7.33(d, 1H), 5.28(s, 1H), 5.21(s, 1H), 2.12(s, 3H)
[0579]
[0580] Example 84. Preparation of 2-(3-hydroxy-4-(2-hydroxypropan-2-yl)phenyl)-4H-benzo[d][1,3]oxazin-4-one
[0581] Example 84 was prepared according to the manufacturing method described in Representative Example 2.
[0582] 1H NMR: DMSO-d6 (δ) 10.08(s, 1H), 8.15(d, 1H), 7.96-7.93(m, 1H), 7.70(d, 1H), 7.63-7.58(m, 4H), 5.64(s, 1H), 1.54(s, 6H)
[0583]
[0584] Example 85. Preparation of 2-(3-hydroxy-4-(2-hydroxypropan-2-yl)phenyl)-4H-thieno[2,3-d][1,3]oxazin-4-one
[0585] Example 85 was prepared according to the manufacturing method described in Representative Example 2.
[0586] 1H NMR: DMSO-d6 (δ) 10.10(s, 1H), 7.71(d, 1H), 7.60-7.58(m, 3H), 7.51(d, 1H), 5.64(br s, 1H), 1.54(s, 6H)
[0587]
[0588] Example 86. Preparation of 6-(3-hydroxy-4-(trifluoromethyl)phenyl)-8H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d][1,3]oxazin-8-one
[0589]
[0590] Example 86 was prepared according to the manufacturing method described in Representative Example 1.
[0591] 1H NMR: DMSO-d6 (δ) 11.08 (s, 1H), 7.83 (s, 1H), 7.73 (m, 2H), 7.51 (s, 1H), 7.26 (s, 1H), 6.30 (s, 2H).
[0592]
[0593] Example 87. Preparation of 5-cyclopropyl-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-thieno[2,3-d][1,3]oxazin-4-one
[0594] Example 87 was prepared according to the manufacturing method described in Representative Example 1.
[0595] 1H NMR: DMSO-d6 (δ) 11.05 (s, 1H), 7.78 (s, 1H), 7.67 (m, 2H), 7.16 (s, 1H), 2.44 (m, 1H), 0.98 (m, 2H), 0.73 (m, 2H).
[0596]
[0597] Example 88. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6-isopropyl-4H-thieno[2,3-d][1,3]oxazin-4-one
[0598] Example 88 was prepared according to the manufacturing method described in Representative Example 1.
[0599] 1H NMR: DMSO-d6 (δ) 11.05 (s, 1H), 7.76 (s, 1H), 7.68 (m, 2H), 7.24 (d, 1H), 3.22 (m, 1H), 1.30 (d, 6H).
[0600]
[0601] Example 89. Preparation of 6-chloro-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-thieno[2,3-d][1,3]oxazin-4-one
[0602] Example 89 was prepared according to the manufacturing method described in Representative Example 1.
[0603] 1H NMR: DMSO-d6 (δ) 11.08 (s, 1H), 7.49 (s, 1H), 7.68 (m, 3H).
[0604]
[0605] Example 90. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-7,8-dihydro-4H-[1,4]dioxino[2',3':4,5]benzo[1,2-d][1,3]oxazin-4-one
[0606] Example 90 was prepared according to the manufacturing method described in Representative Example 1.
[0607] 1H NMR: DMSO-d6 (δ) 11.00 (s, 1H), 7.78 (s, 1H), 7.68 (m, 2H), 7.49 (s, 1H), 7.15 (s, 1H), 4.40 (m, 2H), 4.35 (m, 2H).
[0608]
[0609] Example 91. Preparation of 5-(4-fluoro-3-hydroxyphenyl)-3-methylimidazo[4,5-d][1,3]oxazin-7(3H)-one
[0610] Example 91 was prepared according to the manufacturing method described in Representative Example 1 using the intermediate below.
[0611] 1H NMR: DMSO-d6 (δ) 10.41 (s, 1H), 8.30 (s, 1H), 7.73 (dd, J = 8.7, 2.3 Hz, 1H), 7.57 (qd, J = 4.3, 2.3 Hz, 1H), 7.30 (dd, J = 11.0, 8.7 Hz, 1H), 3.90 (s, 3H)
[0612] [Reaction Equation 3]
[0613]
[0614]
[0615] Step 1. Synthesis of intermediate b
[0616] Compound a (500 mg, 3.54 mmol) and trityl chloride (1037 mg, 3.72 mmol) were dissolved in N,N-dimethylformamide, followed by the addition of triethylamine (0.54 ml, 3.90 mmol) and stirring at room temperature for 1 hour. After the reaction was complete, water was added to precipitate the compound, and the mixture was filtered. The filtered compound was dissolved in dichloromethane, dried with anhydrous MgSO4, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography to obtain intermediate b (1.372 g, 99%).
[0617]
[0618] Step 2. Synthesis of intermediate c
[0619] Intermediate b (1.372 g, 3.54 mmol) was dissolved in N,N-dimethylformamide and cooled with ice water, after which sodium hydride (60%, 0.215 g, 5.37 mmol) was added. Iodomethane (0.268 ml, 4.29 mmol) was added, and the mixture was stirred at room temperature for 2 hours. After the reaction was complete, water was added, and the mixture was extracted with ethyl acetate. The extract was dried with anhydrous MgSO4 and filtered. After concentrating under reduced pressure, the extract was purified by silica gel column chromatography to obtain intermediate c (759 mg, 53%).
[0620] 1H NMR: CDCl3(δ) 7.35 (d, 6H), 7.22-7.26 (m, 7H), 7.18 (t, 3H), 6.83 (s, 1H), 3.81 (s, 3H), 3.63 (s, 3H)
[0621]
[0622] Step 2. Synthesis of intermediate d
[0623] Intermediate c (759 mg, 1.910 mmol) was dissolved in dichloromethane, and trifluoroacetic acid (1 ml) was added and stirred at room temperature for 1 hour. After the reaction was complete, it was concentrated under reduced pressure. The concentrated reaction product was dissolved in dichloromethane, neutralized with saturated NaHCO3, dried with anhydrous MgSO4, and filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography to obtain intermediate d (243 mg, 82%).
[0624]
[0625] Example 92. Preparation of 2-(3-hydroxy-4-(prop-1-en-2-yl)phenyl)-5-methyl-4H-thieno[2,3-d][1,3]oxazin-4-one
[0626] Example 92 was prepared according to the manufacturing method described in Representative Example 2.
[0627] 1H NMR: DMSO-d6 (δ) 10.52(br s, 1H), 7.68(s, 1H), 7.59(d, 1H), 7.35-7.32(m, 2H), 5.28(s, 1H), 5.21(s, 1H), 2.46(s, 3H), 2.11(s, 3H)
[0628]
[0629] Example 93. Preparation of 2-(3-hydroxy-4-(2-hydroxypropan-2-yl)phenyl)-5-methyl-4H-thieno[2,3-d][1,3]oxazin-4-one
[0630] Example 93 was prepared according to the manufacturing method described in Representative Example 2.
[0631] 1H NMR: DMSO-d6 (δ) 10.08(br s, 1H), 7.59-7.57(m, 3H), 7.33(s, 1H), 5.61(br s, 1H), 2.46(s, 3H), 1.53(s, 6H)
[0632]
[0633] Example 94. Preparation of 7-(3-hydroxy-4-(trifluoromethyl)phenyl)-9H-[1,3]dioxolo[4',5':3,4]benzo[1,2-d][1,3]oxazin-9-one
[0634] Example 94 was prepared according to the manufacturing method described in Representative Example 1.
[0635] 1H NMR: DMSO-d6 (δ) 11.04 (s, 1H), 7.81 (s, 1H), 7.72 (m, 2H), 7.51 (d, 1H), 7.23 (d, 1H), 6.38 (d, 2H).
[0636]
[0637] Example 95. Preparation of 6,7-difluoro-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-benzo[d][1,3]oxazin-4-one
[0638] Example 95 was prepared according to the manufacturing method described in Representative Example 1.
[0639] 1H NMR: DMSO-d6 (δ) 11.16 (s, 1H), 8.25 (t, 1H), 7.93 (m, 1H), 7.85 (s, 1H), 7.76 (m, 2H).
[0640]
[0641] Example 96. Preparation of 6,7-difluoro-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-benzo[d][1,3]oxazin-4-one
[0642] Example 96 was prepared according to the manufacturing method described in Representative Example 1.
[0643] 1H NMR: DMSO-d6 (δ) 11.25 (br s, 1H), 8.15 (d, 1H), 7.85 (s, 1H), 7.75 (m, 2H), 7.54 (d, 1H), 2.39 (s, 3H).
[0644]
[0645] Example 97. Preparation of 6-chloro-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-7-methyl-4H-benzo[d][1,3]oxazin-4-one
[0646] Example 97 was prepared according to the manufacturing method described in Representative Example 1.
[0647] 1H NMR: DMSO-d6 (δ) 11.15 (br s, 1H), 8.11 (s, 1H), 7.85 (s, 1H), 7.75 (m, 3H), 2.39 (s, 3H).
[0648]
[0649] Example 98. Preparation of 7-chloro-6-fluoro-2-(3-hydroxy-4-(trifluoromethyl)phenyl)-4H-benzo[d][1,3]oxazin-4-one
[0650] Example 98 was prepared according to the manufacturing method described in Representative Example 1.
[0651] 1H NMR: DMSO-d6 (δ) 11.18 (br s, 1H), 8.17 (d, 1H), 8.89 (d, 1H), 7.85 (s, 1H), 7.75 (m, 2H).
[0652]
[0653] Example 99. Preparation of 2-(4-(tert-butyl)-3-hydroxyphenyl)-7-methyl-4H-thieno[3,2-d][1,3]oxazin-4-one
[0654] Example 99 was prepared according to the manufacturing method described in Representative Example 2.
[0655] 1H NMR: DMSO-d6 (δ) 9.92(s, 1H), 8.09(s, 1H), 7.70(s, 1H), 7.60(d, 1H), 7.36(d, 1H), 2.37(s, 3H), 1.38(s, 9H)
[0656]
[0657] Example 100. Preparation of 2-(4-(tert-butyl)-3-hydroxyphenyl)-4H-thieno[2,3-d][1,3]oxazin-4-one
[0658] Example 100 was prepared according to the manufacturing method described in Representative Example 2.
[0659] 1H NMR: DMSO-d6 (δ) 9.93(s, 1H), 7.71(d, 1H), 7.65(s, 1H), 7.57(d, 1H), 7.51(d, 1H), 7.36(d, 1H), 1.38(s, 9H)
[0660]
[0661] Example 101. Preparation of 2-(4-cyclopropyl-3-hydroxyphenyl)-7-methyl-4H-thieno[3,2-d][1,3]oxazin-4-one
[0662] Example 101 was prepared according to the manufacturing method described in Representative Example 1.
[0663] MS = 298 (M-1).
[0664]
[0665] Example 102. Preparation of 2-(4-cyclopropyl-3-hydroxyphenyl)-4H-thieno[2,3-d][1,3]oxazin-4-one
[0666] Example 102 was prepared according to the manufacturing method described in Representative Example 1.
[0667] 1H NMR: DMSO-d6 (δ) 9.89 (s, 1H), 7.66 (d, 1H), 7.58 (d, 1H), 7.49 (m, 1H), 7.46 (m, 1H), 6.89 (d, 1H), 2.15 (m, 1H), 0.93 (m, 2H), 0.69 (m, 2H).
[0668] MS = 284 (M-1).
[0669]
[0670] Example 103. Preparation of 2-(4-cyclopropyl-3-hydroxyphenyl)-5-methyl-4H-thieno[2,3-d][1,3]oxazin-4-one
[0671] Example 103 was prepared according to the manufacturing method described in Representative Example 1.
[0672] 1H NMR: DMSO-d6 (δ) 9.92 (s, 1H), 8.08 (s, 1H), 7.69 (s, 1H), 7.59 (d, 1H), 6.94 (d, 1H), 2.38 (s, 3H), 2.21 (m, 1H), 1.00 (m, 2H), 0.74 (m, 2H).
[0673] MS = 298 (M-1).
[0674]
[0675] Example 104. Preparation of 5-cyclopropyl-2-(4-cyclopropyl-3-hydroxyphenyl)-4H-thieno[2,3-d][1,3]oxazin-4-one
[0676] Example 104 was prepared according to the manufacturing method described in Representative Example 1.
[0677] 1H NMR: DMSO-d6 (δ) 9.88 (s, 1H), 7.58 (d, 1H), 7.50 (m, 1H), 7.32 (s, 1H), 6.89 (d, 1H), 3.52 (m, 1H), 2.94 (m, 2H), 2.15 (m, 1H), 0.93 (m, 2H), 0.69 (m, 2H).
[0678]
[0679] Example 105. Preparation of 5-(3-hydroxy-4-(trifluoromethyl)phenyl)-1-(2-hydroxyethyl)imidazo[4,5-d][1,3]oxazin-7(1H)-one
[0680] Example 105 was prepared according to the manufacturing method described in Representative Example 1 using the intermediate f of [Reaction Scheme 4] below.
[0681] 1H NMR: DMSO-d6 (δ) 11.06 (s, 1H), 8.34 (s, 1H), 7.80 (s, 1H), 7.68 (dd, 2H), 4.99 (t, 1H), 4.31 (t, 2H), 3.72 (q, 2H).
[0682]
[0683] [Reaction Equation 4]
[0684]
[0685]
[0686] Step 1. Synthesis of intermediate e
[0687] Intermediate b (190 mg, 0.391 mmol) of Example 91 was dissolved in N,N-dimethylformamide and cooled with ice water, then sodium hydride (60%, 20.3 mg, 0.509 mmol) was added and stirred for a few minutes, then 2-bromoethyl acetate (131 mg, 0.782 mmol) dissolved in THF was added and stirred overnight at room temperature. After the reaction was complete, it was neutralized with aq. HCl and water was added. The precipitated compound was filtered and dried to obtain intermediate e (155 mg, 84%).
[0688] 1H NMR: CDCl3(δ) 7.33-7.35 (m, 6H), 7.22-7.26 (m, 7H), 7.19 (d, 3H), 6.89 (s, 1H), 4.25 (s, 4H), 3.81 (s, 3H), 1.92 (s, 3H)
[0689] Step 2. Synthesis of intermediate f
[0690] In Example 91, intermediate f (51 mg, 68%) was obtained using intermediate e (155 mg, 0.33 mmol) by the method of intermediate d.
[0691] 1H NMR: CDCl3(δ) 7.17 (s, 1H), 4.86 (s, 2H), 4.35-4.38 (br, 2H), 4.29 (t, 2H), 3.82 (d, 3H), 2.00 (s, 3H)
[0692]
[0693] Example 106. Preparation of 5-(3-hydroxy-4-(trifluoromethyl)phenyl)-1-methylimidazo[4,5-d][1,3]oxazin-7(1H)-one
[0694] Example 106 was prepared according to the manufacturing method described in Representative Example 1 using intermediate d of Example 91.
[0695] 1H NMR: DMSO-d6 (δ) 10.41 (s, 1H), 8.30 (s, 1H), 7.73 (dd, 1H), 7.57 (qd, 1H), 7.30 (dd, 1H), 3.90 (s, 3H).
[0696]
[0697] Example 107. Preparation of 2-(3-hydroxy-4-(trifluoromethyl)phenyl)-6-methyl-4H-furo[3,2-d][1,3]oxazin-4-one
[0698] Example 107 was prepared according to the manufacturing method described in Representative Example 1.
[0699] 1H NMR: DMSO-d6 (δ) 8.99 (s, 1H), 7.97 (d, 1H), 7.58 (d, 2H), 6.80 (d, 1H), 2.49 (d, 3H).
[0700]
[0701] Example 108. Preparation of 2-(3-hydroxy-5-methoxy-4-(trifluoromethyl)phenyl)-7-methyl-4H-thieno[3,2-d][1,3]oxazin-4-one
[0702] Example 108 was prepared according to the manufacturing method described in Representative Example 2.
[0703] 1H NMR: DMSO-d6 (δ) 10.91(s, 1H), 8.13(s, 1H), 7.53(s, 1H), 7.31(s, 1H), 3.94(s, 3H), 2.40(s, 3H)
[0704]
[0705] Example 109. Preparation of 2-(2,5-dihydroxyphenyl)-7-methyl-4H-thieno[3,2-d][1,3]oxazin-4-one
[0706] Example 109 was prepared according to the manufacturing method described in Representative Example 1.
[0707] 1H NMR: DMSO-d6 (δ) 11.59(s, 1H), 9.34(s, 1H), 8.13(s, 1H), 7.35(d, 1H), 7.02-7.00(m, 1H), 6.92(d, 1H), 2.34(s, 3H)
[0708]
[0709] Example 110. Preparation of 2-(4-cyclopropyl-3-hydroxyphenyl)-4H-thieno[3,2-d][1,3]oxazin-4-one
[0710] Example 110 was prepared according to the manufacturing method described in Representative Example 1.
[0711] 1H NMR: DMSO-d6 (δ) 9.92 (s, 1H), 8.42 (d, 1H), 7.65 (s, 1H), 7.56 (d, 1H), 7.50 (d, 1H), 6.93 (d, 1H), 2.21 (m, 1H), 1.23 (m, 2H), 0.74 (m, 2H).
[0712]
[0713] Example 111. Preparation of 2-(4-cyclopropyl-3-hydroxyphenyl)-4H-thieno[3,2-d][1,3]oxazin-4-one
[0714] Example 111 was prepared according to the manufacturing method described in Representative Example 1.
[0715] MS = 352 (M-1).
[0716]
[0717] Example 112. Preparation of 2-(4-cyclopropyl-3-hydroxyphenyl)-4H-thieno[3,2-d][1,3]oxazin-4-one
[0718] Example 112 was prepared according to the manufacturing method described in Representative Example 1.
[0719] MS = 314 (M-1).
[0720]
[0721] Example 113. Preparation of 2-(4-cyclopropyl-3-hydroxyphenyl)-4H-thieno[3,2-d][1,3]oxazin-4-one
[0722] Example 113 was prepared according to the manufacturing method described in Representative Example 1.
[0723] 1H NMR: DMSO-d6 (δ) 7.95 (d, 1H), 7.83 (m, 1H), 7.62 (d, 1H), 7.43 (d, 1H), 7.37 (d, 1H), 5.18 (s, 1H), 1.47 (s, 9H).
[0724]
[0725] Example 114. Preparation of 2-(4-(tert-butyl)-3-hydroxyphenyl)-5-(trifluoromethyl)-4H-thieno[2,3-d][1,3]oxazin-4-one
[0726] Example 114 was prepared according to the manufacturing method described in Representative Example 1.
[0727] 1H NMR: DMSO-d6 (δ) 7.84 (d, 1H), 7.74 (s, 1H), 7.61 (s, 1H), 7.43 (d, 1H), 5.25 (s, 1H), 1.47 (s, 9H).
[0728]
[0729] Example 115. Preparation of 2-(3-hydroxy-4-(piperidin-1-yl)phenyl)-7-methyl-4H-thieno[3,2-d][1,3]oxazin-4-one
[0730] Example 115 was prepared according to the manufacturing method described in Representative Example 2.
[0731] 1H NMR: DMSO-d6 (δ) 9.69(br s, 1H), 8.06(s, 1H), 7.67(s, 1H), 7.63(d, 1H), 6.96(d, 1H), 3.10-3.07(m, 4H), 2.36(s, 3H), 1.67-1.63(m, 4H), 1.57-1.53(m, 2H)
[0732]
[0733] Example 116. Preparation of 2-(3-hydroxy-4-morpholinophenyl)-7-methyl-4H-thieno[3,2-d][1,3]oxazin-4-one
[0734] Example 116 was prepared according to the manufacturing method described in Representative Example 2.
[0735] 1H NMR: DMSO-d6 (δ) 9.90(br s, 1H), 8.06(s, 1H), 7.70(s, 1H), 7.64(d, 1H), 6.97(d, 1H), 3.75-3.73(m, 4H), 3.15-3.12(m, 4H), 2.36(s, 3H)
[0736]
[0737] [Experimental Example]
[0738] Experimental Example 1. Confirmation of the aryl hydrocarbon receptor activating effect and plasma half-life of the compound of the present invention
[0739] Activated aryl hydrocarbon receptors are responsible for major physiological functions in vivo, such as maintaining cellular homeostasis, skin barrier function, inducing anti-inflammatory responses, and antioxidant responses, and play a key role in defense mechanisms against external stimuli and pathogens, as well as in regulating inflammation. Accordingly, it was confirmed whether the compounds of the present invention bind to and activate aryl hydrocarbon receptors. To evaluate the activity of aryl hydrocarbon receptors, a Luciferase assay was performed using the HepG2 cell line, and Luciferase expression levels were measured after treatment with the compounds of the examples of the present invention. The activation level of the aryl hydrocarbon receptor is EC 50It was represented as.
[0740] Furthermore, the compounds of the present invention are characterized by enhancing the activity of aryl hydrocarbon receptors in the skin or epithelium, but degrading upon exposure to blood to lose their binding affinity to said receptors, thereby having a low risk of side effects. Accordingly, the rate at which the compounds of the present invention degrade in a plasma environment is measured to determine their plasma half-life (T 1 / 2 I checked ).
[0741] In each experiment, Comparative Example 1, which does not essentially contain a hydroxyl group at the 3rd position of the phenyl group, was used as the comparative example. The compound of Comparative Example 1 is the compound described in Example II-5 of U.S. Patent No. 7,872,052 and is represented by the structure described in Table 1 below.
[0742]
[0743] As a result, as shown in Table 1, Comparative Example 1, which does not have a hydroxyl group at the 3rd position of phenyl, failed to activate the aryl hydrocarbon receptor as a result of the luciferase assay, whereas the compounds according to the present invention were found to significantly increase the activity of the aryl hydrocarbon receptor and degrade more rapidly in plasma.
[0744]
[0745] Examples and Comparative Examples Number Structure Lucifera Control EC 50 (nM) Plasma stability 1 / 2 (min) Comparative Example 1 Inactive7 Example 1 0.036 Example 2 0.25-Example 3 112 Example 4 -9 Example 5 0.1423 Example 7 52<1 Example 9 0.05532 Example 10 4.866 Example 11 3.232 Example 12 0.0232 Example 13 0.1414 Example 15 37 Example 16 0.0327 Example 17 2.146 Example 18 13.8-Example 19 1.319 Example 20 23.1-Example 21 0.28 Example 22 27.221 Example 23 4.4-Example 24 4.310 Example 25 0.342 Example 26 0.4-Example 27 5.97 Example 28 157.2-Example 29 15.3-Example 30 2.7-Example 31 0.0310 Example 32 1.578 Example 33 192 Example 34 0.002105 Example 35 0.9678 Example 36 0.1-Example 38 207 Example 39 0.05-Example 40 10.03-Example 41 125.4-Example 42 261.78 Example 43 0.34 Example 44 107 Example 45 0.00258 Example 46 1.9-Example 48 0.01-Example 49 45.4100 Example 51 13.7-Example 52 11.1-Example 53 0.03-Example 55 0.35 Example 56 0.4-Example 57 0.440 Example 58 5.9-Example 60 0.00413 Example 61 0.09-Example 62 0.0719 Example 63 0.1-Example 64 0.394 Example 65 0.17 Example 66 0.00334 Example 67 0.06-Example 68 5.3-Example 69 0.1-Example 70 0.1103 Example 71 2-Example 74 1.8102 Example 75 1.866 Example 76 0.6-Example 77 3-Example 78 0.0311 Example 79 0.522 Example 80 13.46 Example 81 0.630 Example 82 0.24 Example 83 0.0114 Example 84 12.7-Example 85 11.97 Example 86 26.5-Example 87 0.0125 Example 88 10-Example 89 1.4-Example 90 9.4-Example 91 13.5-Example 92 0.991 Example 93 5.7-Example 94 0.0518 Example 95 0.6-Example 96 0.0171 Example 97 0.02-Example 98 11-Example 99 0.0338 Example 100 1.39 Example 101 0.00366 Example 102 0.097 Example 103 0.0278 Example 104 0.14101 Example 105 11.918 Example 106 0.68 Example 107 9.6-Example 108 0.2-Example 109 20-Example 110 0.0214 Example 111 0.0818 Example 112 0.004-Example 113 0.19 Example 114 0.240 Example 115 10.4-Example 116 3.5-
[0746]
[0747] Experimental Example 2. Analysis of the skin barrier-related gene and antioxidant gene expression-promoting ability of the compound of the present invention
[0748] FLGN is a gene encoding Filaggrin, which is produced by keratinocytes to stabilize the structure of the stratum corneum and contribute to the formation of a physical protective barrier of the skin. Additionally, because Filaggrin condenses keratin fibers to increase the strength and elasticity of keratinocytes, it is involved in maintaining moisture on the skin surface and regulating pH. Nqo1 is a gene encoding the NQO1 protein, an oxidoreductase; NQO1 plays a role in inhibiting the accumulation of reactive oxygen species and reactive nitrogen species, and protecting cells from intracellular oxidative stress.
[0749] Accordingly, using the NHEK cell line, which is a human epidermal keratinocyte, the effect of the compounds according to the present invention on the expression of the genes was analyzed. As a comparative example, a compound having the same structure as Experimental Example 1 was used. Meanwhile, Co refers to a control group that was not treated with the compounds of the present invention.
[0750] Specifically, NHEK cell lines were suspended in cell culture medium at a concentration of 120,000 cells / mL, and 1 mL was dispensed into each well of a 24-well plate. The cell culture medium was prepared by adding Human Keratinocyte Growth Supplement (BPE, 0.2% v / v; Recombinant human insulin-like growth factor-I, 0.01 μg / mL; hydrocortisone, 0.18 μg / mL; bovine transferrin, 5 mg / mL; and human epidermal growth factor, 0.2 ng / mL) (Gibco™) to Media 154 (Gibco™) medium. The 24-well plates inoculated with cells were placed in a cell culture incubator and incubated for 3 days at 37°C under 5% CO2 conditions. After 3 days, the cells were observed to have a confluency of 90% or higher using a microscope, washed twice with PBS, and 1 mL of fresh cell culture medium was dispensed into each well. The cell culture medium used at this time was prepared by reducing the BPE to 1 / 10 of the aforementioned medium and removing hydrocortisone (Media 154; BPE, 0.02% v / v; Recombinant human insulin-like growth factor-I, 0.01 μg / mL; bovine transferrin, 5 mg / mL; and human epidermal growth factor, 0.2 ng / mL). The compounds according to one embodiment of the present invention were each treated to the cells to a final concentration of 1 μM and incubated for 6 hours (37℃, 5% CO2).
[0751] After 6 hours, the cell culture medium in each well of the 24-well plate was removed, and the cells were lysed by adding lysis buffer. DNA was removed from the cell lysate, and a precipitate was prepared by mixing 70% EtOH in a 1:1 ratio, after which RNA was isolated using a mini spin column. The isolated RNA was synthesized into cDNA, and the expression levels of the human filaggrin (hFLGN) and Nqo1 (hNqo1) genes were measured using a qPCR (quantitative PCR) instrument and corrected for the human GAPDH gene.
[0752] As a result, as shown in Fig. 1, the comparative example did not affect the expression of FLGN and Nqo1 genes, whereas the compounds of the present invention significantly increased the expression of both genes. The above results demonstrate that the compounds of the present invention can suppress inflammation and improve skin health by increasing the expression of skin barrier-related genes and antioxidant genes.
[0753]
[0754] Experimental Example 3. Analysis of the atopic dermatitis treatment effect of the compound of the present invention
[0755] To verify whether the compounds of the present invention actually have a therapeutic effect on inflammatory diseases or hyperimmune diseases, an analysis was performed using an animal model in which atopy, a representative inflammatory skin disease, was induced.
[0756] Specifically, MC903 was applied to the right ear of BALB / C mice at a concentration of 2 nmol for 12 days to induce atopic dermatitis-like lesions. In the atopic animal model, a compound according to one embodiment of the present invention, a vehicle, or a comparative example compound was topically applied once a day to the atopic induction site (lesion site). To determine the degree of induction and improvement of atopic dermatitis, ear thickness, which reflects the degree of skin edema, was measured during the test period, and on the 12th day of administration, blood was sampled and blood IgE was measured using ELISA. The test was terminated on the 12th day of administration, and at the time of termination, ear weight was measured and parameters reflecting the degree of improvement of atopic dermatitis in the skin tissue were analyzed.
[0757] As a result, as shown in Figure 2, mice administered with the compound of the present invention showed a significant reduction in ear thickness and weight, which reflect the degree of skin inflammation and edema, compared to mice treated with Vehicle or Comparative Example. In addition, IgE levels, which indicate the degree of over-immunity and allergic inflammatory response, were also reduced in mice administered with the compound of the present invention compared to other mice.
[0758] All of the above results show that the compounds of the present invention can alleviate skin inflammation and edema and strengthen the skin barrier, thereby contributing to the treatment of atopic dermatitis.
Claims
1. Compounds represented by the following chemical formula 1, pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, hydrates, solvates, polymorphs, or isotopic variants thereof: [Chemical Formula 1] In the above chemical formula 1, A is C 6-10 It is a 5- to 12-membered heteroaryl comprising 1 to 3 heteroatoms selected from the group consisting of aryl, N, O, and S, or a 7- to 12-membered bicyclic heterocycle comprising 1 to 3 heteroatoms selected from the group consisting of N, O, and S, and R is H, C 1-10 Alkyl, OH, halo, C 1-10 Alkoxy, halo C 1-10 Alkyl, Hydroxy C 1-10 Alkyl, Halo C 1-6 Alkoxy, -C(=O)OR', C 3-8 Cycloalkyl or C 6-10 Arilgo, X is H, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkinil, Halo, CN, C 1-10 Alkoxy, halo C 1-10 Alkyl, Halo C 1-10 Alkoxy, Hydroxy C 1-10 Alkyl, OH, C 3-8 Cycloalkyl, C 6-10 Aryl, 5- to 12-membered heterocycloalkyl or mono- or di-C 1-10 It is an alkylamino, and R' is C 1-10 It is alkyl, and n is an integer from 0 to 3.
2. In Paragraph 1, The above A is a compound, a pharmaceutically acceptable salt thereof, an enantiomer, a diastereomer, a tautomer, a hydrate, a solvate, a polymorph, or an isotope variant, represented by a structure selected from the group consisting of the following structures:
3. In Paragraph 1, The above R is H, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, Halo C 1-6 Alkyl, Hydroxy C 1-6 Alkyl, Halo C 1-6 Alkoxy, -C(=O)OR', OH, F, Cl, Br, or phenyl, and R' is C 1-6 Alkyl compounds, pharmaceutically acceptable salts thereof, enantiomers, diastereomers, tautomers, hydrates, solvates, polymorphs, or isotopic variants.
4. In Paragraph 1, The above R is a compound, pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, hydrate, solvate, polymorph, or isotopic variant thereof, wherein R is H, methyl, ethyl, methoxy, ethoxy, isopropoxy, t-butoxycarbonyl, cyclopropyl, OH, CF3, F, Cl, Br, OCF3, CH2CH2OH.
5. In Paragraph 1, The above X is H, C 1-6 Alkyl, C 1-6 Alkoxy, Halo C 1-6 Alkyl, Hydroxy C 1-6 Alkyl, Halo C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkinil, C 3-6 Cycloalkyl, OH, CN, F, Br, phenyl, 5- to 6-membered heterocycloalkyl or mono- or di-C 1-6 Alkylaminophosphorus, compound, pharmaceutically acceptable salt thereof, enantiomer, diastereomer, tautomer, hydrate, solvate, polymorph, or isotopic variant.
6. In Paragraph 1, The above X is a compound, pharmaceutically acceptable salt, enantiomer, diastereomeric isomer, tautomer, OH, CN, F, Br, phenyl, piperidinyl, or morpholinyl, wherein X is H, methyl, ethyl, isopropyl, t-butyl, CF3, cyclopropyl, methoxy, hydroxyisopropyl, propenyl, ethynyl, OH, CN, F, Br, phenyl, piperidinyl, or morpholinyl.
7. In Paragraph 1, The compound represented by the above chemical formula 1 is a compound, a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, hydrate, solvate, polymorph, or isotope variant represented by any one selected from the group consisting of the following: and .
8. A pharmaceutical composition for the prevention or treatment of skin diseases, inflammatory diseases or autoimmune diseases, comprising as an active ingredient a compound of any one of claims 1 to 7, a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, hydrate, solvate, polymorph, or isotope variant thereof.
9. In Paragraph 8, A pharmaceutical composition in which the above skin disease is atopic dermatitis.
10. In Paragraph 8, A pharmaceutical composition in which the above compound, its pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, hydrate, solvate, polymorph, or isotopic variant induces enhancement of the activity of an aryl hydrocarbon receptor.
11. A food composition for the prevention or improvement of skin diseases, inflammatory diseases or autoimmune diseases, comprising as an active ingredient a compound of any one of claims 1 to 7, a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, hydrate, solvate, polymorph, or isotope variant thereof.
12. A cosmetic composition for preventing or improving skin diseases, comprising as an active ingredient a compound of any one of claims 1 to 7, a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, hydrate, solvate, polymorph, or isotope variant thereof.
13. A composition for enhancing the activity of an aryl hydrocarbon acceptor, comprising as an active ingredient a compound of any one of claims 1 to 7, a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, hydrate, solvate, polymorph, or isotopic variant thereof.
14. A method for preparing a compound of Formula 1, comprising the following steps: 1) A step of obtaining a compound of formula 4A by reacting a compound of formula 5A with acetic anhydride (Ac2O); 2) A step of reacting the compound of Formula 4A with the compound of Formula I to obtain the compound of Formula 3A; 3) A step of dissolving the compound of Formula 3A in THF, methanol, and water, and then reacting it with lithium hydroxide monohydrate to obtain the compound of Formula 2A; and 4) A step of obtaining a compound of Formula 1 by reacting the compound of Formula 2A with a coupling agent: [Chemical Formula 5A] [Chemical Formula 4A] [Chemical Formula I] [Chemical Formula 3A] [Chemical Formula 2A] [Chemical Formula 1] In the above equations, A, R, X, and n are as defined in the first paragraph.
15. A method for preparing a compound of Formula 1 comprising the following manufacturing steps: a) a step of reacting a compound of formula II with a compound of formula I to obtain a compound of formula 4B; b) a step of dissolving the compound of formula 4B above in THF, methanol, and water, and then reacting it with lithium hydroxide monohydrate to obtain the compound of formula 3B; c) a step of reacting the compound of Formula 3B with a coupling agent to obtain a compound of Formula 2B; and d) A step of obtaining a compound of Formula 1 by dimethylating the compound of Formula 2B using BBr3: [Chemical Formula II] [Chemical Formula I] [Chemical Formula 4B] [Chemical Formula 3B] [Chemical Formula 2B] [Chemical Formula 1] In the above equations, A, R, X, and n are as defined in the first paragraph.
